

1      **Multi-tissue analysis reveals short tandem repeats as ubiquitous**  
2      **regulators of gene expression and complex traits**  
3

4      Stephanie Feupe Fotsing<sup>1,2</sup>, Jonathan Margoliash<sup>3</sup>, Catherine Wang<sup>4</sup>, Shubham Saini<sup>3</sup>, Richard  
5      Yanicky<sup>5</sup>, Sharona Shleizer-Burko<sup>5</sup>, Alon Goren<sup>5,6</sup> & Melissa Gymrek<sup>3,5,6</sup>

6

7      <sup>1</sup> Biomedical Informatics and Systems Biology, University of California, San Diego, La Jolla, CA,  
8      USA

9      <sup>2</sup> Bioinformatics and Systems Biology Program, University of California San Diego, La Jolla, CA  
10     USA

11     <sup>3</sup> Department of Computer Science and Engineering, University of California San Diego, La Jolla,  
12     CA USA

13     <sup>4</sup> Department of Bioengineering, University of California San Diego, La Jolla, CA USA

14     <sup>5</sup> Department of Medicine, University of California San Diego, La Jolla, CA USA

15

16     <sup>#</sup> Correspondence should be addressed to [mgymrek@ucsd.edu](mailto:mgymrek@ucsd.edu) or [agoren@ucsd.edu](mailto:agoren@ucsd.edu).

17

18

19 **Abstract**

20 Short tandem repeats (STRs) have been implicated in a variety of complex traits in humans.  
21 However, genome-wide studies of the effects of STRs on gene expression thus far have had  
22 limited power to detect associations and provide insights into putative mechanisms. Here, we  
23 leverage whole genome sequencing and expression data for 17 tissues from the Genotype-Tissue  
24 Expression Project (GTEx) to identify STRs for which repeat number is associated with  
25 expression of nearby genes (eSTRs). Our analysis reveals more than 28,000 eSTRs. We employ  
26 fine-mapping to quantify the probability that each eSTR is causal and characterize a group of the  
27 top 1,400 fine-mapped eSTRs. We identify hundreds of eSTRs linked with published GWAS  
28 signals and implicate specific eSTRs in complex traits including height and schizophrenia,  
29 inflammatory bowel disease, and intelligence. Overall, our results support the hypothesis that  
30 eSTRs contribute to a range of human phenotypes and will serve as a valuable resource for future  
31 studies of complex traits.

## 32 Introduction

33 Genome-wide association studies (GWAS) have identified thousands of genetic loci associated  
34 with complex traits<sup>1</sup>, but determining the causal variants, target genes, and biological mechanisms  
35 responsible for each signal has proven challenging. The vast majority of GWAS signals lie in non-  
36 coding regions<sup>2</sup> which are difficult to interpret. Expression quantitative trait loci (eQTL) studies  
37 attempt to link regulatory genetic variation to gene expression changes as a potential molecular  
38 intermediate that drives biological aberrations leading to disease<sup>3</sup>. Indeed, recent studies have  
39 utilized eQTL catalogs to pinpoint causal genes and relevant tissues for a variety of traits<sup>4-6</sup>.

40

41 An additional major challenge in interpreting GWAS is that lead variants are rarely causal  
42 themselves, but rather tag a set of candidate variants in linkage disequilibrium (LD). A variety of  
43 statistical fine-mapping techniques have been developed to identify the most likely causal variant<sup>7-</sup>  
44 <sup>9</sup> considering factors such as summary association statistics, LD information, and functional  
45 annotations. However, these methods have been limited by focusing on bi-allelic single nucleotide  
46 polymorphisms (SNPs) or short indels. On the other hand, multiple recent studies to dissect  
47 GWAS loci have found complex repetitive<sup>6,10</sup> and structural variants<sup>11-13</sup> to be the underlying  
48 causal variants, highlighting the need to consider additional variant classes.

49

50 Short tandem repeats (STRs), consisting of consecutively repeated units of 1-6bp, represent a  
51 large source of genetic variation. STR mutation rates are orders of magnitude higher than SNPs<sup>14</sup>  
52 and short indels<sup>15</sup> and each individual is estimated to harbor around 100 *de novo* mutations in  
53 STRs<sup>16</sup>. Expansions at several dozen STRs have been known for decades to cause Mendelian  
54 disorders<sup>17</sup> including Huntington's Disease and hereditary ataxias. Importantly, these pathogenic  
55 STRs represent a small minority of the more than 1.5 million STRs in the human genome<sup>18</sup>. Due  
56 to bioinformatics challenges of analyzing repetitive regions, many STRs are often filtered from  
57 genome-wide studies<sup>19</sup>. However, increasing evidence supports a widespread role of common  
58 variation at STRs in complex traits such as gene expression<sup>20-23</sup>.

59

60 STRs may regulate gene expression through a variety of mechanisms<sup>24</sup>. For example, the CCG  
61 repeat implicated in Fragile X Syndrome was shown to disrupt DNA methylation, altering  
62 expression of *FMR1*<sup>25</sup>. Yeast studies have demonstrated that homopolymer repeats act as  
63 nucleosome positioning signals with downstream regulatory effects<sup>26,27</sup>. Dinucleotide repeats may  
64 alter affinity of nearby DNA binding sites<sup>28</sup>. Furthermore, certain STR repeat units may form non-

65 canonical DNA and RNA secondary structures such as G-quadruplexes<sup>29</sup>, R-loops<sup>30</sup>, and Z-  
66 DNA<sup>31</sup>.

67

68 We previously performed a genome-wide analysis to identify more than 2,000 STRs for which the  
69 number of repeats were associated with expression of nearby genes<sup>20</sup>, termed expression STRs  
70 (eSTRs). However, the quality of the datasets available for this study reduced power to detect  
71 associations and prevented accurate fine-mapping of individual eSTRs. First, STR genotypes  
72 were based on low coverage (4-6x) whole genome sequencing data performed using short reads  
73 (50-100bp) which are unable to span across many STRs. As a result, individual STR genotype  
74 calls exhibited poor quality with less than 50% genotyping accuracy<sup>18</sup>. Second, the study was  
75 based on a single cell-type (lymphoblastoid cell lines; LCLs) with potentially limited relevance to  
76 most complex traits<sup>32</sup>. While our and other studies<sup>20,22</sup> demonstrated that eSTRs explain a  
77 significant portion (10-15%) of the *cis* heritability of gene expression, the resulting eSTR catalogs  
78 were not powered to causally implicate eSTRs over other nearby variants.

79

80 Here, we leverage deep whole genome sequencing (WGS) and expression data collected by the  
81 Genotype-Tissue Expression Project (GTEx)<sup>33</sup> to map eSTRs in 17 tissues. Our analysis reveals  
82 more than 28,000 unique eSTRs. We employ fine-mapping to quantify the probability of causality  
83 of each eSTR and characterize the top 1,400 (top 5%) fine-mapped eSTRs. We additionally  
84 identify hundreds of eSTRs that are in strong LD with published GWAS signals and implicate  
85 specific eSTRs in multiple complex traits including height, schizophrenia, inflammatory bowel  
86 disease, and intelligence. To further validate our findings, we employ available GWAS data to  
87 demonstrate evidence of a causal link between an eSTR for *RFT1* and height and use a reporter  
88 assay to experimentally validate an effect of this STR on expression. Finally, our eSTR catalog is  
89 publicly available and can provide a valuable resource for future studies of complex traits.

90

## 91 **Results**

92

### 93 ***Profiling expression STRs across 17 human tissues***

94 We performed a genome-wide analysis to identify associations between the number of repeats in  
95 each STR and expression of nearby genes (expression STRs, or “eSTRs”, which we use to refer  
96 to a unique STR by gene association). We focused on 652 individuals from the GTEx<sup>33</sup> dataset  
97 for which both high coverage WGS and RNA-sequencing of multiple tissues were available (**Fig.**

98 **1a).** We used HipSTR<sup>34</sup> to genotype STRs in each sample. After filtering low quality calls  
99 (**Methods**), 175,226 STRs remained for downstream analysis. To identify eSTRs, we performed  
100 a linear regression between average STR length and normalized gene expression for each  
101 individual at each STR within 100kb of a gene, controlling for sex, population structure, and  
102 technical covariates (**Methods, Supplementary Figs. 1-3**). Analysis was restricted to 17 tissues  
103 where we had data for at least 100 samples (**Supplementary Table 1, Methods**) and to genes  
104 with median RPKM greater than 0. Altogether, we performed an average of 262,593 STR-gene  
105 tests across 15,840 protein-coding genes per tissue.

106

107 Using this approach, we identified 28,375 unique eSTRs associated with 12,494 genes in at least  
108 one tissue at a gene-level FDR of 10% (**Fig. 1b, Supplementary Table 1, Supplementary**  
109 **Dataset 1**). The number of eSTRs detected per tissue correlated with sample size as expected  
110 (Pearson  $r=0.75$ ;  $p=0.00059$ ;  $n=17$ ), with the smallest number of eSTRs detected in the two brain  
111 tissues presumably due to their low sample sizes (**Supplementary Fig. 4**). Notably, although  
112 whole blood and skeletal muscle had the highest number of samples, we identified fewer eSTRs  
113 in those tissues than in others with lower sample sizes. This finding is concordant with previous  
114 results for SNPs in this cohort<sup>33</sup> and may reflect higher cell-type heterogeneity in these tissue  
115 samples. eSTR effect sizes previously measured in LCLs were significantly correlated with effect  
116 sizes in all GTEx tissues ( $p<0.01$  for all tissues, mean Pearson  $r=0.45$ ). We additionally examined  
117 previously reported eSTRs<sup>35-42</sup> that were mostly identified using *in vitro* constructs. Six of eight  
118 examples were significant eSTRs in GTEx ( $p<0.01$ ) in at least one tissue analyzed  
119 (**Supplementary Table 2**).

120

121 eSTRs identified above could potentially be explained by tagging nearby causal variants such as  
122 single nucleotide polymorphisms (SNPs). To identify potentially causal eSTRs we employed  
123 CAVIAR<sup>7</sup>, a statistical fine-mapping framework for identifying causal variants. CAVIAR models  
124 the relationship between LD-structure and association scores of local variants to quantify the  
125 posterior probability of causality for each variant (which we refer to as the CAVIAR score). We  
126 used CAVIAR to fine-map eSTRs against all SNPs nominally associated ( $p<0.05$ ) with each gene  
127 under our model (**Methods, Fig. 1a**). On average across tissues, 12.2% of eSTRs had the highest  
128 causality scores of all variants tested.

129

130 We ranked eSTRs by the best CAVIAR score across tissues and chose the top 5% (best CAVIAR  
131 score $>0.3$ ) for downstream analysis. We hereby refer to this group as fine-mapped eSTRs (FM-

132 eSTRs) (**Supplementary Table 1, Supplementary Dataset 2**). Expected gene annotations are  
133 more strongly enriched in this subset of eSTRs compared to the entire set (**Supplementary Fig.**  
134 **5**), and stricter thresholds reduced power to detect eSTR-enriched features described below. Of  
135 FM-eSTRs in each tissue, on average 78% explained more gene expression variation beyond  
136 that of the best SNP (ANOVA  $q < 0.1$ ). Furthermore, on average each FM-eSTR had CAVIAR  
137 score 0.41 higher (41% higher posterior probability) than the top-scoring eSNP (**Supplementary**  
138 **Fig. 6**). Multiple STRs with known disease implications were captured by this list (**Fig. 1c**). In  
139 many cases, FM-eSTRs show clear relationships between the number of repeats and gene  
140 expression across a wide range of repeat lengths (**Supplementary Fig. 7**).

141

142 We next analyzed sharing of eSTRs (defined by a unique STR-gene pair) across tissues. To  
143 minimize power differences across tissues and enable cross-tissue comparisons of eSTR effects,  
144 we applied multivariate adaptive shrinkage (mash<sup>43</sup>) (**Fig. 1a**). Mash takes as input effect sizes  
145 and standard errors as computed above and recomputes posterior estimates of each while  
146 considering global correlations of effect sizes across tissues. We computed correlations of mash  
147 effect sizes for FM-eSTRs across all pairs of tissues (**Fig. 1d**) and recovered previously observed  
148 relationships<sup>43</sup>. For example, tissues with similar origins (e.g., Adipose-Visceral/Adipose-  
149 Subcutaneous) are highly concordant, whereas Whole Blood effects are less correlated with other  
150 tissues. These results are also supported by replication between single-tissue eSTRs using  
151 unadjusted effect sizes (**Supplementary Fig. 8**). We further examined tissue sharing of FM-  
152 eSTRs by counting the number of tissues for which mash computed a posterior Z-score with  
153 absolute value  $> 4$ . Most eSTRs are either shared across all tissues analyzed or are shared by  
154 only a small number of tissues (**Supplementary Fig. 9**), again similar to previously reported eSNP  
155 analyses in this cohort<sup>33</sup>.

156

### 157 **FM-eSTRs demonstrate unique genomic characteristics and sequence features**

158 We next sought to characterize properties of STRs that might provide insights into their biological  
159 function. We reasoned that characteristics such as genomic localization, sequence features, and  
160 direction of effects that distinguish FM-eSTRs from all analyzed STRs would support the  
161 hypothesis that a subset of them are acting as causal variants. We first considered whether the  
162 localization of FM-eSTRs differed from that of STRs overall (**Fig. 2a-b, Supplementary Fig. 10**).  
163 Overall, the majority of FM-eSTRs occur in intronic or intergenic regions, and only 11 FM-eSTRs  
164 fall in coding exons (**Supplementary Table 3**). However, compared to all STRs, those closest to  
165 TSSs and near DNaseI HS sites were more likely to act as FM-eSTRs (**Fig. 2c-d**). FM-eSTRs

166 are strongly enriched at 5' UTRs (OR=5.0; Fisher's two-sided  $p=4.9\text{e-}13$ ), 3' UTRs (OR=2.78;  
167  $p=5.85\text{e-}10$ ), and within 3kb of transcription start sites (OR=3.39;  $p=1.10\text{e-}46$ ). These  
168 enrichments are considerably stronger for FM-eSTRs compared to all eSTRs (**Supplementary**  
169 **Table 4**), suggesting as expected that FM-eSTRs are more likely to be causal.

170  
171 To further explore characteristic of FM-eSTRs in regulatory regions, we examined nucleosome  
172 occupancy in the lymphoblastoid cell line GM12878 and DNA accessibility measured by DNasel-  
173 seq in a variety of cell types within 500bp of FM-eSTRs (**Supplementary Fig. 11**). As expected  
174 from previous studies<sup>44</sup>, regions near homopolymer repeats are strongly nucleosome-depleted.  
175 Notably, STRs with other repeat lengths showed distinct patterns of nucleosome positioning  
176 (**Supplementary Fig. 11a-c**). Nucleosome occupancy is broadly similar for FM-eSTRs compared  
177 to all STRs. FM-eSTRs are generally located in regions with higher DNasel-seq read count  
178 compared to non-eSTRs (Mann-Whitney [MW] two-sided  $p=3.9\text{e-}37$  in GM12878;  
179 **Supplementary Fig. 11d-e**). DNasel hypersensitivity around homopolymer FM-eSTRs shows a  
180 periodic pattern in GM12878 and other tissue types, with notable peaks located at multiples of  
181 147bp upstream of downstream from the STR (**Supplementary Fig. 11d**). Given that 147bp is  
182 the length of DNA typically wrapped around a single nucleosome<sup>44</sup>, we hypothesize that a subset  
183 of homopolymer FM-eSTRs may act by shifting nucleosome positions and thus modulating  
184 openness of adjacent hypersensitive sites.

185  
186 We next examined the sequence characteristics of FM-eSTRs compared to all STRs. We tested  
187 FM-eSTRs combined across all tissues for enrichment of each canonical STR repeat unit (defined  
188 lexicographically, see **Methods**). FM-eSTRs are most strongly enriched for repeats with GC-rich  
189 repeat units (**Fig. 2e, Supplementary Table 5**). For example, the canonical repeat units  
190 CCCCCG, CCCCCG, and CCG are 22, 13, and 7-fold enriched in FM-eSTRs compared to all  
191 STRs respectively. Notably, the total lengths of FM-eSTRs are significantly higher compared to  
192 all STRs analyzed (MW two-sided  $p=0.00032$  and  $p=2.4\text{e-}10$  when comparing total repeat number  
193 and total length in bp in hg19, respectively).

194  
195 We next examined effect sizes biases in FM-eSTR associations. Overall, FM-eSTRs are equally  
196 likely to show positive vs. negative correlations between repeat length and expression  
197 (**Supplementary Fig. 12**; two-sided binomial  $p=0.94$ ). We additionally observed that FM-eSTRs  
198 with repeat units of the form (A<sub>n</sub>C/G<sub>n</sub>T) show strand-specific effects when in or near transcribed  
199 regions. Transcribed FM-eSTRs are more likely to have the T-rich version of the repeat unit on

200 the template strand (two-sided binomial  $p=0.0015$ ). Further, compared to A-rich repeat units on  
201 the template strand, T-rich FM-eSTRs tend to have more positive effect sizes, with the most  
202 notable differences for AC vs. GT repeats. These patterns are observed in transcribed regions  
203 across multiple distinct repeat types (A/T, AC/GT, AAC/GTT, AAAC/GGGT) but are not present  
204 in intergenic regions (**Fig. 2f**).

205  
206 Finally, we wondered whether eSTRs might exhibit distinct characteristics in different tissues. We  
207 clustered tissue-specific Z-scores (absolute value) for each FM-eSTR calculated jointly across  
208 tissues by mash (**Methods**) to identify eight categories of FM-eSTR (**Supplementary Fig. 13**,  
209 **14**). These include two clusters of FM-eSTRs present across many tissues (Clusters 2 and 8) as  
210 well as several more tissue-specific clusters (e.g., Thyroid for Cluster 1). Notably, clusters do not  
211 necessarily imply tissue specificity, but rather enrich for FM-eSTRs with particularly strong effects  
212 in one or more tissues compared to others (**Supplementary Fig. 14**). More than 50% of all genes  
213 in each cluster are expressed in all 17 tissues analyzed, and 88% of FM-eSTRs are shared by  
214 more than one tissue (**Supplementary Fig. 9**). Clusters show similar repeat unit enrichment to  
215 all FM-eSTRs and do not exhibit distinct enriched repeat units (**Supplementary Fig. 15**). We  
216 further tested whether repeat units of FM-eSTRs are distributed uniformly across clusters. Only  
217 one repeat unit (AAAAT) shows a suggestive non-uniform distribution across clusters (Chi-  
218 squared  $p=0.018$ ) with highest prevalence in the thyroid cluster. Similar results were achieved  
219 using different numbers of clusters. Overall, our results suggest the majority of eSTRs act by  
220 global mechanisms and do not implicate tissue-specific characteristics of FM-eSTRs. However,  
221 low numbers of tissue-specific effects limit power to detect differences. Future work may provide  
222 insights into potential tissue-specific mechanisms.

223  
224 **GC-rich eSTRs are predicted to modulate DNA and RNA secondary structure**  
225 FM-eSTRs are most strongly enriched for repeats with high GC content (e.g., canonical repeat  
226 units CCG, CCCCCG, CCCCCCG, AGGGC) (**Fig. 2e, Supplementary Table 5**) which are found  
227 almost exclusively in promoter regions (**Supplementary Fig. 10**). These GC-rich repeat units  
228 have been shown to form highly stable secondary structures during transcription such as G4  
229 quadruplexes in single-stranded DNA<sup>45</sup> or RNA<sup>46</sup> that may regulate gene expression. We  
230 hypothesized that the effects of GC-rich eSTRs may be in part due to formation of non-canonical  
231 nucleic acid secondary structures that modulate DNA or RNA stability as a function of repeat  
232 number. We considered properties of two classes of GC-rich FM-eSTRs: (*i*) those following the  
233 standard G4 motif ( $G_3N_{1-7}G_3N_{1-7}G_3N_{1-7}G_3$ )<sup>47</sup> and (*ii*) repeats with canonical repeat unit CCG which

234 does not meet the standard G4 definition. Notably, the majority of CCG FM-eSTRs (79%) occur  
235 in 5' UTRs compared to only 11% for G4 repeats. We observed that both classes of GC-rich  
236 repeats are associated with higher RNAPII (**Fig. 3a**) and lower nucleosome occupancy (**Fig. 3b**)  
237 compared to all STRs. The relationship with RNAPII was observed across a diverse range of cell  
238 and tissue types (**Supplementary Fig. 16**).

239  
240 To evaluate whether GC-rich repeats could be modulating DNA or RNA secondary structure, we  
241 used mfold<sup>48</sup> to calculate the free energy of each STR and 50bp of its surrounding context in  
242 single stranded DNA or RNA. We considered all common allele lengths (number of repeats)  
243 observed at each STR (**Methods**) and computed energies for both the template and non-template  
244 strands. We then computed the correlation between the number of repeats and free energy at  
245 each STR region. Overall, both G4 and CGG STRs have lower mean free energy (greater stability)  
246 and more negative correlations between repeat number and free energy compared to all STRs  
247 (**Fig. 3c-f, Supplementary Fig. 17**; adjusted MW one-sided  $p<0.05$ ). Compared to all STRs, FM-  
248 eSTRs tend to have lower free energy and more negative correlations with repeat number (MW  
249  $p<0.05$  in all categories except for CGG STRs). Notably, both metrics (mean free energy and  
250 correlation of repeat number vs. free energy) are significantly correlated with the total length of  
251 STR in all cases (Pearson correlation  $p<0.01$ ). FM-eSTRs tend to be longer than STRs overall  
252 (see above), which may partially explain the secondary structure trends observed.

253  
254 Based on previous observations<sup>49</sup>, we predicted that higher repeat numbers at GC-rich eSTRs  
255 would result in greater DNA or RNA stability and in turn would increase expression of nearby  
256 genes. To that end, we tested whether FM-eSTRs were biased toward negative vs. positive effect  
257 sizes. As described above, overall FM-eSTRs show no bias in effect direction. However, when  
258 considering only repeats in promoter regions (TSS +/- 3kb), 59% of FM-eSTRs have positive  
259 effect sizes, significantly more than the 50% expected by chance (binomial two-sided  $p=0.04$ ;  
260  $n=137$ ). This effect was stronger when considering only G4 FM-eSTRs (87% positive effect sizes;  
261  $p=0.0074$ ;  $n=15$ ) but not significant for CCG FM-eSTRs (62% positive;  $n=13$ ;  $p=0.58$ ; **Fig. 3g**).  
262 For multiple G4 FM-eSTRs, expression levels across allele lengths follow an inverse relationship  
263 with free energy (**Fig. 3h-j**). Altogether, these results support a model in which higher repeat  
264 numbers at GC-rich eSTRs in promoter regions stabilize DNA secondary structures which  
265 promote transcription. Lastly, the contradictory results for CCG STRs may indicate that those  
266 repeats could act by distinct mechanisms compared to G4 STRs, but also may be due in part to  
267 limited power from a smaller sample size.

268 **eSTRs are potential drivers of published GWAS signals**

269 Finally, we wondered whether our eSTR catalog could identify STRs affecting complex traits in  
270 humans. We first leveraged the NHGRI/EBI GWAS catalog<sup>50</sup> to identify FM-eSTRs that are nearby  
271 and in LD with published GWAS signals. Overall, 1,381 unique FM-eSTRs are within 1Mb of  
272 GWAS hits (**Methods, Supplementary Dataset 3**). Of these, 847 are in moderate LD ( $r^2>0.1$ )  
273 and 65 are in strong LD ( $r^2>0.8$ ) with the lead SNP. For 7 loci in at least moderate LD, the lead  
274 GWAS variant is within the STR itself (**Supplementary Table 6**).

275

276 We next sought to determine whether specific published GWAS signals could be driven by  
277 changes in expression due to an underlying but previously unobserved FM-eSTR. We reasoned  
278 that such loci would exhibit the following properties: (i) strong similarity in association statistics  
279 across variants for both the GWAS trait and expression of a particular gene, indicating the signals  
280 may be co-localized, *i.e.*, driven by the same causal variant; and (ii) strong evidence that the FM-  
281 eSTR causes variation in expression of that gene (**Fig. 4a**). Co-localization analysis requires high-  
282 resolution summary statistic data. Thus, we focused on several example complex traits (height<sup>51</sup>,  
283 schizophrenia<sup>52</sup>, inflammatory bowel disease (IBD)<sup>53</sup>, and intelligence<sup>54</sup>) for which detailed  
284 summary statistics computed on cohorts of tens of thousands or more individuals are publicly  
285 available (**Methods**).

286

287 For each trait, we identified FM-eSTRs within 1Mb of published GWAS signals from  
288 **Supplementary Dataset 3**. We then used coloc<sup>55</sup> to compute the probability that the FM-eSTR  
289 signals we derived from GTEx and the GWAS signals derived from other cohorts are co-localized.  
290 The coloc tool compares association statistics at each SNP in a region for expression and the  
291 trait of interest and returns a posterior probability that the signals are co-localized. We used coloc  
292 to test a total of 276 genetrait pairs (138, 45, 29, and 64 for height, intelligence, IBD, and  
293 schizophrenia respectively). In total, we identified 28 GWAS loci with (1) an FM-eSTR in at least  
294 moderate LD ( $r^2>0.1$ ) with a nearby SNP for that trait in the GWAS catalog and (2) co-localization  
295 probability between the target gene and the trait >90% (**Supplementary Table 7**,  
296 **Supplementary Fig. 18-19**).

297

298 A top example in our analysis was an FM-eSTR for *RFT1*, an enzyme involved in the pathway of  
299 N-glycosylation of proteins<sup>56</sup>, that has 97.8% co-localization probability with a GWAS signal for  
300 height (**Fig. 4b-c**). The lead SNP in the NHGRI catalog (rs2336725) is in high LD ( $r^2=0.85$ ) with  
301 an AC repeat that is a significant eSTR in 15 tissues. This STR falls in a cluster of transcription

302 factor and chromatin regulator binding regions identified by ENCODE near the 3' end of the gene  
303 (**Fig. 4d**) and exhibits a positive correlation with expression across a range of repeat numbers.

304  
305 To more directly test for association between this FM-eSTR and height, we used our recently  
306 developed STR-SNP reference haplotype panel<sup>57</sup> to impute STR genotypes into available GWAS  
307 data. We focused on the eMERGE cohort (**Methods**) for which imputed genotype array data and  
308 height measurements are available. We tested for association between height and SNPs as well  
309 as for AC repeat number after excluding samples with low STR imputation quality (**Methods**).  
310 Imputed AC repeat number is significantly associated with height in the eMERGE cohort  
311 ( $p=0.00328$ ;  $\beta=0.010$ ;  $n=6,393$ ), although with a slightly weaker p-value compared to the top  
312 SNP (**Fig. 4e**). Notably, even in the case that the STR is the causal variant, power is likely reduced  
313 due to the lower quality of imputed STR genotypes. Encouragingly, AC repeat number shows a  
314 strong positive relationship with height across a range of repeat lengths (**Fig. 4f**), similar to the  
315 relationship between repeat number and *RFT1* expression.

316  
317 To further investigate whether the FM-eSTR for *RFT1* could be a causal driver of gene expression  
318 variation, we devised a dual reporter assay in HEK293T cells to test for an effect of the number  
319 of repeats on gene expression (0, 5, 10, or 12 repeats plus approximately 170bp of genomic  
320 sequence context on either side (**Supplementary Table 8, Methods**). We observed a positive  
321 linear relationship between the number of AC repeats and reporter expression as predicted (**Fig.**  
322 **4g**) (Pearson  $r=0.97$ ;  $p=0.013$ ). Furthermore, all pairs of constructs with consecutive repeat  
323 numbers showed significantly different expression (one-sided t-test  $p<0.01$ ) with the exception of  
324 10 vs. 12 repeats. Overall, these results further support the hypothesis that eSTRs may act as  
325 causal drivers of gene expression.

326  
327 **Discussion**

328 Here we present the most comprehensive resource of eSTRs to date, which reveals more than  
329 28,000 associations between the number of repeats at STRs and expression of nearby genes  
330 across 17 tissues. We performed fine-mapping to quantify the probability that each eSTR causally  
331 effects gene expression and characterize top fine-mapped eSTRs. eSTRs analyzed here consist  
332 of a large spectrum of repeat classes with a variety of repeat unit lengths and sequences, ranging  
333 from homopolymers to hexanucleotide repeats. It is probable that each type induces distinct  
334 regulatory effects (**Fig. 5**). While we explored several potential mechanisms, including

335 nucleosome positioning and the formation of non-canonical DNA or RNA secondary structures,  
336 our results do not rule out other potential mechanisms for these eSTRs.

337

338 We leveraged our resource to provide evidence that FM-eSTRs may drive a subset of published  
339 GWAS associations for a variety of complex traits. Altogether, our complex trait analysis  
340 demonstrates that STRs may represent an important class of variation that is largely missed by  
341 current GWAS. STRs have a unique ability compared to bi-allelic variants such as SNPs or small  
342 indels to drive phenotypic variation along a spectrum of multiple alleles, each with different  
343 numbers of repeats. In multiple examples, the eSTR shows a linear trend between repeat length  
344 and expression across a range of repeat numbers, a signal that cannot be easily explained by  
345 tagging nearby bi-allelic variants. Importantly, the cases identified here likely represent a minority  
346 of eSTRs driving complex traits. Our analysis is based only on signals that could be detected by  
347 standard SNP-based GWAS, which are underpowered to detect underlying multi-allelic  
348 associations from STRs<sup>57</sup>. Further work to directly test for associations between STRs and  
349 phenotypes is likely to reveal a widespread role for repeat number variation in complex traits.

350

351 Our study faced several limitations. *(i)* eSTR discovery was restricted to linear associations  
352 between repeat number and expression. Our analysis did not consider non-linear effects or the  
353 effect of sequence imperfections, such as SNPs or small indels, within the STR sequence itself.  
354 *(ii)* While we applied stringent fine-mapping approaches to find eSTRs whose signals are likely  
355 not explained by nearby SNPs in LD, some signals could plausibly be explained by other variant  
356 classes such as structural variants<sup>58</sup> or *Alu* elements<sup>59</sup> that were not considered. Furthermore,  
357 our fine-mapping procedure may be vulnerable to false negatives for STRs in strong or perfect  
358 LD with nearby SNPs or false positives due to noise present with small sample sizes. *(iii)* Our  
359 study was limited to tissues available from GTEx with sufficient sample sizes. While this greatly  
360 expanded on the single tissue used in our previous eSTR analysis, some tissues such as brain  
361 were not well represented and had low power for eSTR detection. Further, while we analyzed 17  
362 distinct tissues, due to overwhelming sharing of eSTRs across tissues, we were unable to identify  
363 tissue-specific characteristics of eSTRs *(iv)* Despite strong evidence that the FM-eSTRs for *RFT1*  
364 and other genes may drive published GWAS signals, we have not definitively proved causality.  
365 Additional work is needed to validate effects on expression and evaluate the impact of these STRs  
366 in trait-relevant cell types. Nevertheless, most FM-eSTRs have broad effects across many tissue  
367 types and in many cases are the most plausible causal variants identified by fine-mapping. This

368 suggests our list of FM-eSTRs colocalized with GWAS signals (**Supplementary Table 7**) will be  
369 useful for identifying candidate eSTRs driving complex traits to be explored in future studies.

370  
371 In summary, our eSTR catalog provides a valuable resource for both obtaining deeper insights  
372 into biological roles of eSTRs in regulating gene expression and for identifying potential causal  
373 variants underlying a variety of complex traits.

374  
375 **Materials and Methods**

376 ***Dataset and preprocessing***

377 Next-generation sequencing data was obtained from the Genotype-Tissue Expression (GTEx)  
378 through dbGaP under phs000424.v7.p2. This included high coverage (30x) Illumina whole  
379 genome sequencing (WGS) data and expression data from 652 unrelated individuals  
380 (**Supplementary Fig. 1**). The WGS cohort consisted of 561 individuals with reported European  
381 ancestry, 75 of African ancestry, and 8, 3, and 5 of Asian, Amerindian, and Unknown ancestry,  
382 respectively. For each sample, we downloaded BAM files containing read alignments to the hg19  
383 reference genome and VCFs containing SNP genotype calls.

384  
385 STRs were genotyped using HipSTR<sup>34</sup>, which returns the maximum likelihood diploid STR allele  
386 sequences for each sample based on aligned reads as input. Samples were genotyped separately  
387 with non-default parameters --min-reads 5 and --def-stutter-model. VCFs were filtered using the  
388 filter\_vcf.py script available from HipSTR using recommended settings for high coverage data  
389 (min-call-qual 0.9, max-call-flank-indel 0.15, and max-call-stutter 0.15). VCFs were merged  
390 across all samples and further filtered to exclude STRs meeting the following criteria: call rate  
391 <80%; STRs overlapping segmental duplications (UCSC Genome Browser<sup>60</sup>  
392 hg19.genomicSuperDups table); penta- and hexamer STRs containing homopolymer runs of at  
393 least 5 or 6 nucleotides, respectively in the hg19 reference genome, since we previously found  
394 these STRs to have high error rates due to indels in homopolymer regions<sup>57</sup>; and STRs whose  
395 frequencies did not meet the percentage of homozygous vs. heterozygous calls based on  
396 expected under Hardy-Weinberg Equilibrium (binomial two-sided p<0.05). Additionally, to restrict  
397 to polymorphic STRs we filtered STRs with heterozygosity <0.1. Altogether, 175,226 STRs  
398 remained for downstream analysis.

399

400 We additionally obtained gene-level RPKM values for each tissue from dbGaP project  
401 phs000424.v7.p2. We focused on 15 tissues with at least 200 samples, and included two brain  
402 tissues with slightly more than 100 samples available (**Supplementary Table 1**). Genes with  
403 median RPKM of 0 were excluded and expression values for remaining genes were quantile  
404 normalized separately per tissue to a standard normal distribution. Analysis was restricted to  
405 protein-coding genes based on GENCODE version 19 (Ensembl 74) annotation.

406

407 Prior to downstream analyses, expression values were adjusted separately for each tissue to  
408 control for sex, population structure, and technical variation in expression as covariates. For  
409 population structure, we used the top 10 principal components resulting from performing principal  
410 components analysis (PCA) on the matrix of SNP genotypes from each sample. PCA was  
411 performed jointly on GTEx samples and 1000 Genomes Project<sup>61</sup> samples genotyped using Omni  
412 2.5 genotyping arrays (see **URLs**). Analysis was restricted to bi-allelic SNPs present in the Omni  
413 2.5 data and resulting loci were LD-pruned using plink<sup>62</sup> with option --indep 50 5 2. PCA on  
414 resulting SNP genotypes was performed using smartpca<sup>63,64</sup>. To control for technical variation in  
415 expression, we applied PEER factor correction<sup>65</sup>. Based on an analysis of number of PEER  
416 factors vs. number of eSTRs identified per tissue (**Supplementary Fig. 2**), we determined an  
417 optimal number of N/10 PEER factors as covariates for each tissue, where N is the sample size.  
418 PEER factors were correlated with covariates reported previously for GTEx samples  
419 (**Supplementary Fig. 3**) such as ischemic time.

420

## 421 **eSTR and eSNP identification**

422 For each STR within 100kb of a gene, we performed a linear regression between STR lengths  
423 and adjusted expression values:

$$424 \quad Y' = \beta X + \epsilon$$

425 Where  $X$  denotes STR genotypes,  $Y'$  denotes expression values adjusted for the covariates  
426 described above,  $\beta$  denotes the effect size, and  $\epsilon$  is the error term. A separate regression analysis  
427 was performed for each STR-gene pair in each tissue. For STR genotypes, we used the average  
428 repeat length of the two alleles for each individual, where repeat length was computed as a length  
429 difference from the hg19 reference, with 0 representing the reference allele. Linear regressions  
430 were performed using the OLS function from the Python statsmodels.api module<sup>66</sup>. As a control,  
431 for each STR-gene pair we performed a permutation analysis in which sample identifiers were  
432 shuffled.

433

434 Samples with missing genotypes or expression values were removed from each regression  
435 analysis. To reduce the effect of outlier STR genotypes, we removed samples with genotypes  
436 observed in less than 3 samples. If after filtering samples there were less than three unique  
437 genotypes, the STR was excluded from analysis. Adjusted expression values and STR genotypes  
438 for remaining samples were then Z-scaled to have mean 0 and variance 1 before performing each  
439 regression. This step forces resulting effect sizes to be between -1 and 1.

440

441 We used a gene-level FDR threshold (described previously<sup>20</sup>) of 10% to identify significant STR-  
442 gene pairs. We assume most genes have at most a single causal eSTR. For each gene, we  
443 determined the STR association with the strongest P-value. This P-value was adjusted using a  
444 Bonferroni correction for the number of STRs tested per gene to give a P-value for observing a  
445 single eSTR association for each gene. We then used the list of adjusted P-values (one per gene)  
446 as input to the fdrcorrection function in the statsmodels.stats.multitest module to obtain a q-value  
447 for the best eSTR for each gene. FDR analysis was performed separately for each tissue.

448

449 eSNPs were identified using the same model covariates, and normalization procedures but using  
450 SNP dosages (0, 1, or 2) rather than STR lengths. Similar to the STR analysis, we removed  
451 samples with genotypes occurring in fewer than 3 samples and removed SNPs with less than 3  
452 unique genotypes remaining after filtering. On average, we tested 17 STRs and 533 SNPs per  
453 gene.

454

### 455 ***Fine-mapping eSTRs***

456 We used model comparison as an orthogonal validation to CAVIAR findings to determine whether  
457 the best eSTR for each gene explained variation in gene expression beyond a model consisting  
458 of the best eSNP. For each gene with an eSTR we determined the eSNP with the strongest p-  
459 value. We then compared two linear models:  $Y' \sim \text{eSNP}$  (SNP-only model) vs.  $Y' \sim \text{eSNP} + \text{eSTR}$   
460 (SNP+STR model) using the anova\_lm function in the python statsmodels.api.stats module. Q-  
461 values were obtained using the fdrcorrection function in the statsmodels.stats.multitest module.  
462 On average across tissues, 17.4% of eSTRs tested improved the model over the best eSNP for  
463 the target gene (10% FDR). When restricting to FM-eSTRs, 78% improved the model (10% FDR).

464

465 We used CAVIAR<sup>7</sup> v2.2 to further fine-map eSTR signals against the all nominally significant  
466 eSNPs ( $p < 0.05$ ) within 100kb of each gene. On average, 121 SNPs per gene passed this  
467 threshold and were included in CAVIAR analysis. Pairwise-LD between the eSTR and eSNPs

468 was estimated using the Pearson correlation between SNP dosages (0, 1, or 2) and STR  
469 genotypes (average of the two STR allele lengths) across all samples. CAVIAR was run with  
470 parameters -f 1 -c 2 to model up to two independent causal variants per locus. In some cases,  
471 initial association statistics for SNPs and STRs might have been computed using different sets of  
472 samples if some were filtered due to outlier genotypes. To provide a fair comparison between  
473 eSTRs and eSNPs, for each CAVIAR analysis we recomputed Z-scores for eSTRs and eSNPs  
474 using the same set of samples prior to running CAVIAR.

475

#### 476 ***Multi-tissue eSTR analysis***

477 We used an R implementation of *mash*<sup>43</sup> (*mashR*) v0.2.21 to compute posterior estimates of eSTR  
478 effect sizes and standard errors across tissues. Briefly, *mashR* takes as input effect sizes and  
479 standard error measurements per-tissue, learns various covariance matrices of effect sizes  
480 between tissues, and outputs posterior estimates of effect sizes and standard errors accounting  
481 for global patterns of effect size sharing. We used all eSTRs with a nominal p-value of <1e-5 in  
482 at least one tissue as a set of strong signals to compute covariance matrices. eSTRs that were  
483 not analyzed in all tissues were excluded from this step. We included “canonical” covariance  
484 matrices (identity matrix and matrices representing condition-specific effects) and matrices  
485 learned by extreme deconvolution initialized using PCA with 5 components as suggested by  
486 *mashR* documentation. After learning covariance matrices, we applied *mashR* to estimate  
487 posterior effect sizes and standard errors for each eSTR in each tissue. For eSTRs that were  
488 filtered from one or more tissues in the initial regression analysis, we set input effect sizes to 0  
489 and standard errors to 10 in those tissues to reflect high uncertainty in effect size estimates at  
490 those eSTRs. For **Fig. 1d**, rows and columns of the effect size correlation matrix were clustered  
491 using default parameters from the *clustermap* function in the Python *seaborn* library (see **URLs**).  
492

#### 493 ***Canonical repeat units***

494 For each STR, we defined the canonical repeat unit as the lexicographically first repeat unit when  
495 considering all rotations and strand orientations of the repeat sequence. For example, the  
496 canonical repeat unit for the repeat sequence CAGCAGCAGCAG would be AGC.  
497

#### 498 ***Enrichment analyses***

499 Enrichment analyses were performed using a two-sided Fisher’s exact test as implemented in the  
500 *fisher\_exact* function of the python package *scipy.stats* (see **URLs**). Overlapping STRs with each  
501 annotation was performed using the *intersectBed* tool of the *BEDTools*<sup>67</sup> suite. Genomic

502 annotations were obtained by downloading custom tables using the UCSC Genome Browser<sup>60</sup>  
503 table browser tool to select either coding regions, introns, 5'UTRs, 3'UTRs, or regions upstream  
504 of TSSs. An STR could be assigned to more than one category in the case of overlapping  
505 transcripts. STRs not assigned to one of those categories were labeled as intergenic. ENCODE  
506 DNasel HS clusters were downloaded from the UCSC Genome Browser (see **URLs**). Analysis  
507 was restricted to DNasel HS clusters annotated in at least 20 cell types. The distance between  
508 each STR and the center of the nearest DNasel HS cluster was computed using the closestBed  
509 tool from the BEDTools suite.

510

### 511 ***Analysis of DNasel-seq, ChIP-seq, and Nucleosome occupancy***

512 Genome-wide nucleosome occupancy signal in GM12878 was downloaded from the UCSC  
513 Genome Browser (see **URLs**). ChIP-seq reads for RNAPII and DNasel-seq reads were  
514 downloaded from the ENCODE Project website (see **URLs**) (Accessions GM12878 RNAPII:  
515 ENCFF775ZJX, heart RNAPII: ENCFF643EGO, lung RNAPII: ENCSR033NHF, tibial nerve  
516 RNAPII: ENCFF750HDH, human embryonic stem cells RNAPII: ENCFF526YGE; GM12878  
517 DNasel: ENCFF775ZJX, fat DNasel: ENCFF880CAD, tibial nerve DNasel: ENCFF226ZCG, skin  
518 DNasel: ENCFF238BRB). Histograms of aggregate read densities and heatmaps for individual  
519 STR regions were generated using the annoatePeaks.pl tool of Homer<sup>68</sup>. For nucleosome  
520 occupancy and DNasel analyses on all STRs, we used parameters -size 1000 -hist 1. For analysis  
521 of GC-rich repeats in promoters, we used parameters -size 10000 -hist 5.

522

### 523 ***Characterization of tissue-specific eSTRs***

524 We clustered FM-eSTRs based on effect sizes Z-scores computed by mash for each eSTR in  
525 each tissue. We first created a tissue by FM-eSTR matrix of the absolute value of the Z-scores.  
526 We then Z-normalized Z-scores for each FM-eSTR to have mean 0 and variance 1. We used the  
527 KMeans class from the Python sklearn.cluster module to perform K-means clustering with K=8.  
528 The number of clusters was chosen by visualizing the sum of squared distances from centroids  
529 for values of K ranging from 1 to 20 and choosing a value of K based on the “elbow method”.  
530 Using different values of K produced similar groups. We tested for non-uniform distributions of  
531 FM-eSTR repeat units across clusters using a chi-squared test implemented in the scipy.stats  
532 chi2\_contingency function.

533

### 534 ***Analysis of DNA and RNA secondary structure***

535 For each STR, we extracted the repeat plus 50bp flanking sequencing from the hg19 reference  
536 genome. We additionally created sequences containing each common allele for each STR.  
537 Common alleles were defined as those seen at least 5 times in a previously generated deep  
538 catalog of STR variation in 1,916 samples<sup>57</sup>. For each sequence and its reverse complement, we  
539 ran mfold<sup>48</sup> on the DNA and corresponding RNA sequences with mfold arguments NA=DNA and  
540 NA=RNA, respectively, and otherwise default parameters to estimate the free energy of each  
541 single-stranded sequence. Mann-Whitney tests were performed using the mannwhitneyu function  
542 of the scipy.stats python package (see **URLs**).

543

544 ***Co-localization of FM-eSTRs with published GWAS signals***

545 Published GWAS associations were obtained from the NHGRI/EBI GWAS catalog available from  
546 the UCSC Genome Browser Table Browser (table hg19.gwasCatalog) downloaded on July 24,  
547 2019. Height GWAS summary statistics were downloaded from the GIANT Consortium website  
548 (see **URLs**). Schizophrenia GWAS summary statistics were downloaded from the Psychiatric  
549 Genomics Consortium website (see **URLs**). IBD summary statistics were downloaded from the  
550 International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) website. We used the  
551 file EUR.IBD.gwas\_info03\_filtered.assoc with summary statistics in Europeans (see **URLs**).  
552 Intelligence summary statistics were downloaded from the Complex Trait Genomics lab website  
553 (see **URLs**). LD between STRs and SNPs was computed by taking the squared Pearson  
554 correlation between STR lengths and SNP dosages in GTEx samples for each STR-SNP pair.  
555 STR genotypes seen less than 3 times were filtered from LD calculations.

556

557 Co-localization analysis of eQTL and GWAS signals was performed using the coloc.abf function  
558 of the coloc<sup>55</sup> package. For all traits, dataset 1 was specified as type="quant" and consisted of  
559 eSNP effect sizes and their variances as input. We specified sdY=1 since expression was quantile  
560 normalized to a standard normal distribution. Dataset 2 was specified differently for height and  
561 schizophrenia to reflect quantitative vs. case-control analyses. For height and intelligence, we  
562 specified type="quant" and used effect sizes and their variances as input. We additionally  
563 specified minor allele frequencies listed in the published summary statistics file and the total  
564 sample size of N=695,647 and N=269,720 for height and intelligence, respectively. For  
565 schizophrenia and IBD, we specified type="CC" and used effect sizes and their variances as input.  
566 We additionally specified the fraction of cases as 33%.

567

568 Capture Hi-C interactions (**Supplementary Fig. 19**) were visualized using the 3D Genome  
569 Browser<sup>69</sup>. The visualization depicts interactions profiled in GM12878<sup>70</sup> and only shows  
570 interactions overlapping the STR of interest.

571

## 572 ***Association analysis in the eMERGE cohort***

573 We obtained SNP genotype array data and imputed genotypes from dbGaP accessions  
574 phs000360.v3.p1 and phs000888.v1.p1 from consent groups c1 (Health/Medical/Biomedical), c3  
575 (Health/Medical/Biomedical - Genetic Studies Only - No Insurance Companies), and c4  
576 (Health/Medical/Biomedical - Genetic Studies Only). Height data was available for samples in  
577 cohorts c1 (phs000888.v1.ph004680.v1.p1.c1), c3 (phs000888.v1.ph004680.v1.p1.c3), and c4  
578 (phs000888.v1.ph004680.v1.p1.c4). We removed samples without age information listed. If  
579 height was collected at multiple times for the same sample, we used the first data point listed.

580

581 Genotype data was available for 7,190, 6100, and 3,755 samples from the c1, c3, and c4 cohorts  
582 respectively (dbGaP study phs000360.v3.p1). We performed PCA on the genotypes to infer  
583 ancestry of each individual. We used plink to restrict to SNPs with minor allele frequency at least  
584 10% and with genotype frequencies expected under Hardy-Weinberg Equilibrium ( $p > 1e-4$ ). We  
585 performed LD pruning using the plink option --indep 50 5 1.5 and used pruned SNPs as input to  
586 PCA analysis. We visualized the top two PCs and identified a cluster of 14,147 individuals  
587 overlapping samples with annotated European ancestry. We performed a separate PCA using  
588 only the identified European samples and used the top 10 PCs as covariates in association tests.

589

590 A total of 11,587 individuals with inferred European ancestry had both imputed SNP genotypes  
591 and height and age data available. Samples originated from cohorts at Marshfield Clinic, Group  
592 Health Cooperative, Northwestern University, Vanderbilt University, and the Mayo Clinic. We  
593 adjusted height values by regressing on top 10 ancestry PCs, age, and cohort. Residuals were  
594 inverse normalized to a standard normal distribution. Adjustment was performed separately for  
595 males and females.

596

597 Imputed genotypes (from dbGaP study phs000888.v1.p1) were converted from IMPUTE2<sup>71</sup> to  
598 plink's binary format using plink, which marks calls with uncertainty  $> 0.1$  (score  $< 0.9$ ) as missing.  
599 SNP associations were performed using plink with imputed genotypes as input and with the  
600 "linear" option with analysis restricted to the region chr3:53022501-53264470.

601

602 The *RFT1* FM-eSTR was imputed into the imputed SNP genotypes using Beagle 5<sup>72</sup> with option  
603 gp=true and using our SNP-STR reference haplotype panel<sup>57</sup>. We previously estimated  
604 imputation concordance of 97% at this STR in a separate European cohort. Samples with imputed  
605 genotype probabilities of less than 0.9 were removed from the STR analysis. We additionally  
606 restricted analysis to STR genotypes present in at least 100 samples to minimize the effect of  
607 outlier genotypes. We regressed STR genotype (defined above as the average of an individual's  
608 two repeat lengths) on residualized height values for the remaining 6,393 samples using the  
609 Python statsmodels.regression.linear\_model.OLS function (see **URLs**).

610

### 611 ***Dual luciferase reporter assay***

612 Constructs for 0, 5, or 10 copies of AC at the FM-eSTR for *RFT1* (chr3:53128363-53128413 plus  
613 approximately 170bp genomic context on either side (RFT1\_0rpt, RFT1\_5rpt, RFT1\_10rpt in  
614 **Supplementary Table 8**) were ordered as gBlocks from Integrated DNA technologies (IDT). Each  
615 construct additionally contained homology arms for cloning into pGL4.27 (below). We additionally  
616 PCR amplified the region from genomic DNA for sample NA12878 with 12 copies of AC (NIGMS  
617 Human Genetic Repository, Coriell) using PrimeSTAR max DNA Polymerase (Clontech R045B)  
618 and primers RFT1eSTR\_F and RFT1eSTR\_R (**Supplementary Table 8**) which included the  
619 same homology arms.

620

621 Constructs were cloned into plasmid pGL4.27 (Promega, E8451), which contains the firefly  
622 luciferase coding sequence and a minimal promoter. The plasmid was linearized using EcoRV  
623 (New England Biolabs, R3195) and purified from agarose gel (Zymo Research, D4001).  
624 Constructs were cloned into the linearized vector using In-Fusion (Clontech, 638910). Sanger  
625 sequencing of isolated clones for each plasmid validated expected repeat numbers in each  
626 construct.

627

628 Plasmids were transfected into the human embryonic kidney 293 cell line (HEK293T; ATCC CRL-  
629 3216) and grown in DMEM media (Gibco, 10566-016), supplemented with 10% fetal bovine serum  
630 (Gibco, 10438-026), 2 mM glutamine (Gibco, A2916801), 100 units/mL of penicillin, 100 µg/mL of  
631 streptomycin, and 0.25 µg/mL Amphotericin B (Anti-Anti Gibco, 15240062). Cells were maintained  
632 at 37°C in a 5% CO<sub>2</sub> incubator. 2×10<sup>5</sup> HEK293T cells were plated onto each well of a 25 ug/ml  
633 poly-D lysine (EMD Millipore, A-003-E) coated 24-well plate, the day prior to transfection. On the  
634 day of the transfection medium was changed to Opti-MEM. We conducted co-transfection

635 experiments to test expression of each construct. 100ng of the empty pGL4.27 vector (Promega,  
636 E8451) or 100 ng of each one of the pGL4.27 derivatives, were mixed with 5ng of the reference  
637 plasmid, pGL4.73 (Promega, E6911), harboring SV40 promoter upstream of Renilla luciferase,  
638 and added to the cells in the presence of Lipofectamine™ 3000 (Invitrogen, L3000015), according  
639 to the manufacturer's instructions. Cells were incubated for 24 hr at 37°C, washed once with  
640 phosphate-buffered saline, and then incubated in fresh completed medium for an additional 24  
641 hr.

642  
643 48 hours after transfection the HEK293T cells were washed 3 times with PBS and lysed in 100µl  
644 of Passive Lysis Buffer (Promega, E1910). Firefly luciferase and Renilla luciferase activities were  
645 measured in 10µl of HEK293T cell lysate using the Dual-Luciferase Reporter assay system  
646 (Promega, E1910) in a Veritas™ Microplate Luminometer. Relative activity was defined as the  
647 ratio of firefly luciferase activity to Renilla luciferase activity. For each plasmid, transfection and  
648 the expression assay were done in triplicates using three wells of cultured cells that were  
649 independently transfected (biological repeats), and three individually prepared aliquots of each  
650 transfection reaction (technical repeats). Values from each technical replicate were averaged to  
651 get one ratio for each biological repeat. Values shown in **Fig. 4g** represent the mean and standard  
652 deviation across the three biological replicates for each construct.

653

## 654 **Data Availability**

655 All eSTR summary statistics are available for download on WebSTR  
656 <http://webstr.ucsd.edu/downloads>.

657

## 658 **Code Availability**

659 Code for performing analyses and generated figures is available at  
660 <http://github.com/gymreklab/gtex-estrs-paper>.

## 661 **URLs**

662 1000 Genomes phased Omni2.5 SNP data,  
663 [ftp://1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/shapeit2\\_scaffolds/hd\\_chip\\_scaffolds/](ftp://1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/shapeit2_scaffolds/hd_chip_scaffolds/)

665 ENCODE DNasel HS clusters,  
666 <http://hgdownload.cse.ucsc.edu/goldenpath/hg19/encodeDCC/wgEncodeRegDnaseClustered/wgEncodeRegDnaseClusteredV3.bed.gz>  
667 ChIP-seq and DNasel-seq, <https://www.encodeproject.org>  
668 Nucleosome occupancy in GM12878,  
669 <http://hgdownload.cse.ucsc.edu/goldenpath/hg19/encodeDCC/wgEncodeSydhNsome/wgEncodeSydhNsomeGm12878Sig.bigWig>  
670 Height GWAS summary statistics,  
671 [https://portals.broadinstitute.org/collaboration/giant/images/0/0f/Meta-analysis\\_Locke\\_et\\_al%2BUKBiobank\\_2018.txt.gz](https://portals.broadinstitute.org/collaboration/giant/images/0/0f/Meta-analysis_Locke_et_al%2BUKBiobank_2018.txt.gz)  
672 Schizophrenia GWAS summary statistics, <https://www.med.unc.edu/pgc/results-and-downloads>  
673 IBD summary statistics, <ftp://ftp.sanger.ac.uk/pub/consortia/ibdgenetics/iibdgc-trans-ancestry-filtered-summary-stats.tgz>  
674 Intelligence summary statistics,  
675 [https://ctg.cncr.nl/documents/p1651/SavageJansen\\_IntMeta\\_sumstats.zip](https://ctg.cncr.nl/documents/p1651/SavageJansen_IntMeta_sumstats.zip)  
676 Python scipy.stats package, <https://docs.scipy.org/doc/scipy/reference/stats.html>  
677 Python statsmodels package, <https://www.statsmodels.org>  
678 Python scikit-learn package, <https://scikit-learn.org/stable/>  
679 Python seaborn package, <https://seaborn.pydata.org/>  
680 MashR vignettes, [https://stephenslab.github.io/mashr/articles/intro\\_mash\\_dd.html#data-driven-covariances](https://stephenslab.github.io/mashr/articles/intro_mash_dd.html#data-driven-covariances)  
681

682 **Acknowledgements**  
683 Research reported in this publication was supported in part by the Office Of The Director, National  
684 Institutes of Health under Award Number DP5OD024577. We thank Vineet Bafna, Eric  
685 Mendenhall, Joseph Gleeson, and Yu-Ting Liu for helpful comments.

686  
687 **GTEX Project**  
688 The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the  
689 Office of the Director of the National Institutes of Health ([commonfund.nih.gov/GTEx](http://commonfund.nih.gov/GTEx)). Additional  
690 funds were provided by the NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. Donors were enrolled  
691 at Biospecimen Source Sites funded by NCI\Leidos Biomedical Research, Inc. subcontracts to  
692 the National Disease Research Interchange (10XS170), GTEx Project March 5, 2014 version  
693 Page 5 of 8 Roswell Park Cancer Institute (10XS171), and Science Care, Inc. (X10S172). The

698 Laboratory, Data Analysis, and Coordinating Center (LDACC) was funded through a contract  
699 (HHSN268201000029C) to the The Broad Institute, Inc. Biorepository operations were funded  
700 through a Leidos Biomedical Research, Inc. subcontract to Van Andel Research Institute  
701 (10ST1035). Additional data repository and project management were provided by Leidos  
702 Biomedical Research, Inc. (HHSN261200800001E). The Brain Bank was supported supplements  
703 to University of Miami grant DA006227. Statistical Methods development grants were made to  
704 the University of Geneva (MH090941 & MH101814), the University of Chicago  
705 (MH090951,MH090937, MH101825, & MH101820), the University of North Carolina - Chapel Hill  
706 (MH090936), North Carolina State University (MH101819),Harvard University (MH090948),  
707 Stanford University (MH101782), Washington University (MH101810), and to the University of  
708 Pennsylvania (MH101822). The datasets used for the analyses described in this manuscript were  
709 obtained from dbGaP at <http://www.ncbi.nlm.nih.gov/gap> through dbGaP accession number  
710 phs000424.v7.p2.

711 ***eMERGE Project - Mayo Clinic***

712 Samples and associated genotype and phenotype data used in this study were provided by the  
713 Mayo Clinic. Funding support for the Mayo Clinic was provided through a cooperative agreement  
714 with the National Human Genome Research Institute (NHGRI), Grant #: U01HG004599; and by  
715 grant HL75794 from the National Heart Lung and Blood Institute (NHLBI). Funding support for  
716 genotyping, which was performed at The Broad Institute, was provided by the NIH  
717 (U01HG004424). The datasets used for analyses described in this manuscript were obtained from  
718 dbGaP at <http://www.ncbi.nlm.nih.gov/gap> through dbGaP accession numbers phs000360.v3.p1  
719 and phs000888.v1.p1.

720

721 ***eMERGE Project - Marshfield Clinic***

722 Funding support for the Personalized Medicine Research Project (PMRP) was provided through  
723 a cooperative agreement (U01HG004608) with the National Human Genome Research Institute  
724 (NHGRI), with additional funding from the National Institute for General Medical Sciences  
725 (NIGMS) The samples used for PMRP analyses were obtained with funding from Marshfield  
726 Clinic, Health Resources Service Administration Office of Rural Health Policy grant number D1A  
727 RH00025, and Wisconsin Department of Commerce Technology Development Fund contract  
728 number TDF FY010718. Funding support for genotyping, which was performed at Johns Hopkins  
729 University, was provided by the NIH (U01HG004438). The datasets used for analyses described

730 in this manuscript were obtained from dbGaP at <http://www.ncbi.nlm.nih.gov/gap> through dbGaP  
731 accession numbers phs000360.v3.p1 and phs000888.v1.p1.

732

733 ***eMERGE Project - Northwestern University***

734 Samples and data used in this study were provided by the NUgene Project ([www.nugene.org](http://www.nugene.org)).  
735 Funding support for the NUgene Project was provided by the Northwestern University's Center  
736 for Genetic Medicine, Northwestern University, and Northwestern Memorial Hospital. Assistance  
737 with phenotype harmonization was provided by the eMERGE Coordinating Center (Grant number  
738 U01HG04603). This study was funded through the NIH, NHGRI eMERGE Network  
739 (U01HG004609). Funding support for genotyping, which was performed at The Broad Institute,  
740 was provided by the NIH (U01HG004424). The datasets used for analyses described in this  
741 manuscript were obtained from dbGaP at <http://www.ncbi.nlm.nih.gov/gap> through dbGaP  
742 accession numbers phs000360.v3.p1 and phs000888.v1.p1.

743

744 ***eMERGE Project - Vanderbilt University***

745 Funding support for the Vanderbilt Genome-Electronic Records (VGER) project was provided  
746 through a cooperative agreement (U01HG004603) with the National Human Genome Research  
747 Institute (NHGRI) with additional funding from the National Institute of General Medical Sciences  
748 (NIGMS). The dataset and samples used for the VGER analyses were obtained from Vanderbilt  
749 University Medical Center's BioVU, which is supported by institutional funding and by the  
750 Vanderbilt CTSA grant UL1RR024975 from NCRR/NIH. Funding support for genotyping, which  
751 was performed at The Broad Institute, was provided by the NIH (U01HG004424). The datasets  
752 used for analyses described in this manuscript were obtained from dbGaP at  
753 <http://www.ncbi.nlm.nih.gov/gap> through dbGaP accession numbers phs000360.v3.p1 and  
754 phs000888.v1.p1.

755

756 ***eMERGE Project - Group Health Cooperative***

757 Funding support for Alzheimer's Disease Patient Registry (ADPR) and Adult Changes in Thought  
758 (ACT) study was provided by a U01 from the National Institute on Aging (Eric B. Larson, PI,  
759 U01AG006781). A gift from the 3M Corporation was used to expand the ACT cohort. DNA aliquots  
760 sufficient for GWAS from ADPR Probable AD cases, who had been enrolled in Genetic  
761 Differences in Alzheimer's Cases and Controls (Walter Kukull, PI, R01 AG007584) and obtained  
762 under that grant, were made available to eMERGE without charge. Funding support for  
763 genotyping, which was performed at Johns Hopkins University, was provided by the NIH

764 (U01HG004438). Genome-wide association analyses were supported through a Cooperative  
765 Agreement from the National Human Genome Research Institute, U01HG004610 (Eric B. Larson,  
766 PI). The datasets used for analyses described in this manuscript were obtained from dbGaP at  
767 <http://www.ncbi.nlm.nih.gov/gap> through dbGaP accession numbers phs000360.v3.p1 and  
768 phs000888.v1.p1.

769

## 770 **Author Contributions**

771 S.F.F. performed all eSTR and eSNP mapping, helped perform downstream analyses and helped  
772 draft the manuscript. J.M. performed multi-tissue analysis using mashR and helped revise the  
773 manuscript. C.W. optimized and performed the reporter assay. S.S. participated in design of the  
774 STR imputation analysis. S.S.-B. lead, designed, and analyzed data from the reporter assay. R.Y.  
775 implemented the WebSTR web application. A.G. conceived and planned analyses and validation  
776 experiments of regulatory effects of eSTRs and wrote the manuscript. M.G. conceived the study,  
777 designed and performed analyses, and drafted the initial manuscript. All authors have read and  
778 approved the final manuscript.

## 779 **Competing interests**

780 The authors have no competing financial interests to disclose.

781

782

783 **Figure Legends**

784

785 **Figure 1: Multi-tissue identification of eSTRs.**

786 **(a) Schematic of eSTR discovery pipeline.** We analyzed RNA-seq from 17 tissues and STR  
787 genotypes obtained from deep WGS for 652 individuals from the GTEx Project. For each STR  
788 within 100kb of a gene, we tested for association between length of the STR and expression of  
789 the gene in each tissue. For each gene, CAVIAR was used to fine-map the effects of eSTRs vs.  
790 nominally significant *cis* SNPs on gene expression. CAVIAR takes as input pairwise variant LD  
791 and effect sizes (Z-scores) and outputs a posterior probability of causality for each variant. For  
792 multi-tissue analysis, per-tissue effect sizes and standard errors were used as input to mashR,  
793 which computes posterior effect size estimates in each tissue based on potential sharing of  
794 eSTRs across tissues.

795 **(b) eSTR association results.** The quantile-quantile plot compares observed p-values for each  
796 STR-gene test vs. the expected uniform distribution. Gray dots denote permutation controls. The  
797 black line shows the diagonal. Colored dots show observed p-values for each tissue.

798 **(c) Example eSTRs previously implicated in disease.** Left: a CG-rich FM-eSTR upstream of  
799 *CSTB* was previously implicated in myoclonus epilepsy<sup>73</sup>. Middle: a multi-allelic intronic CCTGGG  
800 FM-eSTR in *NOP56* was implicated in spinocerebellar ataxia 36<sup>74</sup>. Right: A CGGGGG FM-eSTR  
801 in the promoter of *ALOX5* was previously shown to regulate *ALOX5* expression in leukocytes<sup>42</sup>  
802 and is associated with reduced lung function<sup>75</sup> and cardiovascular disease<sup>76</sup>. Each black point  
803 represents a single individual. For each plot, the x-axis represents the mean number of repeats  
804 in each individual and the y-axis represents normalized expression in a representative tissue.  
805 Boxplots summarize the distribution of expression values for each genotype. Horizontal lines  
806 show median values, boxes span from the 25th percentile (Q1) to the 75th percentile (Q3).  
807 Whiskers extend to Q1-1.5\*IQR (bottom) and Q3+1.5\*IQR (top), where IQR gives the interquartile  
808 range (Q3-Q1). The red line shows the mean expression for each x-axis value. Gene diagrams  
809 are not drawn to scale.

810 **(d) eSTR effect sizes are correlated across tissues and studies.** Each cell in the matrix shows  
811 the Spearman correlation between mashR FM-eSTR effect sizes ( $\beta'$ ) for each pair of tissues. Only  
812 eSTRs with CAVIAR score  $>0.3$  in at least one tissue (FM-eSTRs) were included in each  
813 correlation analysis. Rows and columns were clustered using hierarchical clustering (**Methods**).

814

815 **Figure 2: Characterization of FM-eSTRs**

816 **(a) Density of all STRs around transcription start sites.** The y-axis shows the number of STRs  
817 in each 100bp bin around the TSS relative to the average across all bins. Negative x-axis numbers  
818 denote upstream regions and positive numbers denote downstream regions.  
819 **(b) Density of all STRs around DNasel HS sites.** Plots are centered at ENCODE DNasel HS  
820 clusters and represent the relative number of STRs in each 50bp bin. For **(a)** and **(b)** the black  
821 line denotes all STRs and colored lines denote repeats with different repeat unit lengths  
822 (gray=homopolymers, red=dinucleotides, gold=trinucleotides, blue=tetranucleotides,  
823 green=pentanucleotides, purple=hexanucleotides).  
824 **(c) Relative probability to be an FM-eSTR around TSSs.** The black lines represent the  
825 probability of an STR in each bin to be an FM-eSTR. Values were scaled relative to the genome-  
826 wide average.  
827 **(d) Relative probability to be an FM-eSTR around DNasel HS clusters.** Axes are similar to  
828 those in **(c)** except centered around DNasel HS clusters. For **a-d**, values were smoothed by  
829 taking a sliding average of each four consecutive bins.  
830 **(e) Repeat unit enrichment at FM-eSTRs across all tissues.** The x-axis shows all repeat units  
831 for which there are at least 3 FM-eSTRs across all tissues. The y-axis denotes the  $\log_2$  odds ratios  
832 (OR) from performing a Fisher's exact test comparing FM-eSTRs to all STRs. Enrichments for all  
833 eSTRs are given in **Supplementary Table 5**. Single asterisks denote repeat units nominally  
834 enriched or depleted (two-sided Fisher exact test  $p<0.05$ ). Double asterisks denote repeat units  
835 significantly enriched after controlling for the number of repeat units tested (Bonferroni adjusted  
836  $p<0.05$ ).  
837 **(f) Strand-biased characteristics of FM-eSTRs.** Top panel: the y-axis shows the number of FM-  
838 eSTRs with each repeat unit on the template strand. Bottom panel: the y-axis shows the  
839 percentage of FM-eSTRs with each repeat unit on the template strand that have positive effect  
840 sizes. Gray bars denote A-rich repeat units (A/AC/AAC/AAAC) and red bars denote T-rich repeat  
841 units (T/GT/GTT/GTTT). Single asterisks denote repeat units nominally enriched or depleted (two-  
842 sided binomial  $p<0.05$ ). Double asterisks denote repeat units significantly enriched after  
843 controlling for multiple hypothesis testing (Bonferroni adjusted  $p<0.05$ ). Asterisks above brackets  
844 show significant differences between repeat unit pairs. Asterisks on x-axis labels denote  
845 departure from the 50% positive effect sizes expected by chance. Error bars give 95% confidence  
846 intervals.  
847

848 **Figure 3: GC-rich eSTRs are predicted to modulate DNA secondary structure.**

849 **(a) Density of RNAPII localization around STRs.** The y-axis denotes the average number of  
850 ChIP-seq reads for RNA Polymerase II in GM12878 in 5bp bins centered at STRs.

851 **(b) Nucleosome occupancy around STRs.** The y-axis denotes the average nucleosome  
852 occupancy in 5bp bins centered at STRs in GM12878. For **(a)** and **(b)**, black lines denote all STRs  
853 found within 5kb of TSSs, blue lines denote CCG STRs, and red lines denote STRs matching the  
854 canonical G4 motif. Dashed lines represent all STRs of each class and solid lines represent FM-  
855 eSTRs. Only STRs within 5,000bp of a TSS are included.

856 **(c-d) Free energy of STR regions.** Boxplots denote the distribution of free energy for each STR  
857 +/- 50bp of context sequence, computed as the average across all alleles at each STR. **(c)** and  
858 **(d)** show results computed using the template strand for DNA and RNA, respectively.

859 **(e-f) Pearson correlation between STR length and free energy.** Correlations were computed  
860 separately for each STR, and plots show the distribution of correlation coefficients across all  
861 STRs. The dashed horizontal line denotes 0 correlation as expected by chance. **(e)** and **(f)** show  
862 results computed using the template strand for DNA and RNA, respectively.

863 For **c-f**, horizontal purple lines show medians and boxes span from the 25th percentile (Q1) to  
864 the 75th percentile (Q3). Whiskers extend to  $Q1 - 1.5 \times IQR$  (bottom) and  $Q3 + 1.5 \times IQR$  (top), where  
865 IQR represents the interquartile range (Q3-Q1). White boxes show all STRs in each category and  
866 black boxes show FM-eSTRs. Upper brackets denote significant differences for all STRs (white)  
867 across categories or for significant differences within each category between all STRs (white) and  
868 FM-eSTRs (black). Numbers below **(c)** denote the number of data points (unique STRs) included  
869 in each box. Nominally significant differences (Mann Whitney one-sided  $p < 0.05$ ) between  
870 distributions are denoted with a single asterisk. Differences significant after controlling for multiple  
871 hypothesis correction are denoted with double asterisks. For each category (free energy and  
872 Pearson correlation), we used a Bonferroni correction to control for 20 total comparisons:  
873 comparing all vs. FM-eSTRs separately in each category, comparing CCG vs. all STRs, and  
874 comparing G4 vs. all STRs, in four conditions (DNA +/- and RNA +/-). Results for non-template  
875 strands are shown in **Supplementary Fig. 17**.

876 **(g) Bias in the direction of eSTR effect sizes.** The y-axis shows the percentage of FM-eSTRs  
877 in each category with positive effect sizes, meaning a positive correlation between STR length  
878 and expression. White bars denote all STRs in each category. Gray bars denote STRs falling  
879 within 3kb of TSSs. Error bars give 95% confidence intervals.

880 **(h-j) Examples of G4 FM-eSTRs in promoter regions predicted to modulate secondary  
881 structure.** For each example, top plots show the mean expression across all individuals with each  
882 mean STR length. Vertical bars represent +/- 1 s.d. Bottom plots show the free energy computed

883 by mfold for each number of repeats for the STR. Note, expression plots (top) have additional  
884 points to represent heterozygous genotypes, whereas energies (bottom) were computed per-  
885 allele rather than per-genotype. Solid and dashed gray lines show energies for alleles on the  
886 template and non-template strands, respectively. The x-axis shows STR lengths relative to the  
887 hg19 reference genome in bp. Gene diagrams are not drawn to scale.

888

889 **Figure 4: FM-eSTRs co-localize with published GWAS signals.**

890 **(a) Overview of analyses to identify FM-eSTRs involved in complex traits.** In cases where  
891 FM-eSTRs may drive complex phenotypes, we assumed a model where variation in STR repeat  
892 number (red; left) alters gene expression (purple; middle), which in turn affects the value of a  
893 particular complex trait (right). Even when the STR is the causal variant, nearby SNPs (gray; left)  
894 in LD may be associated with both gene expression through eQTL analysis and the trait of interest  
895 through GWAS. Black arrows indicate assumed causal relationships. Dashed arrows indicate  
896 analysis approaches (1-3) used to test each relationship. (1) eQTL analysis tests for associations  
897 between SNP genotype or STR repeat number and gene expression. (2) GWAS tests for  
898 associations between SNP genotype and trait value. (3) coloc analysis tests whether the  
899 association signals for expression and the trait are driven by the same underlying causal variant.

900 **(b) eSTR association for *RFT1*.** The x-axis shows STR genotype at an AC repeat  
901 (chr3:53128363) as the mean number of repeats and the y-axis gives normalized *RFT1*  
902 expression in a representative tissue (Esophagus-Muscularis). Each point represents a single  
903 individual. Boxplots summarize expression distributions for each genotype as described in **Fig.**  
904 **1d.** Red lines show the mean expression for each x-axis value.

905 **(c) Summary statistics for *RFT1* expression and height.** The top panel shows genes in the  
906 region around *RFT1*. The middle panel shows the  $-\log_{10}$  p-values of association between each  
907 variant and *RFT1* expression in aortic artery. The FM-eSTR is denoted by a red star. The bottom  
908 panel shows the  $-\log_{10}$  p-values of association for each variant with height based on available  
909 summary statistics<sup>51</sup>. The dashed gray horizontal line shows genome-wide significance  
910 threshold.

911 **(d) Detailed view of the *RFT1* locus.** A UCSC genome browser<sup>60</sup> screenshot is shown for the  
912 region in the gray box in **(b)**. The FM-eSTR is shown in red. The bottom track shows transcription  
913 factor (TF) binding clusters profiled by ENCODE.

914 **(e) eSTR and SNP associations with height at the *RFT1* locus in the eMERGE cohort.** The  
915 x-axis shows the same genomic region as in **(b)**. The y-axis denotes association p-values for  
916 each variant in the subset of eMERGE cohort samples analyzed here. Black dots represent SNPs.

917 The blue star denotes the top variant in the region identified by Yengo, *et al.*<sup>51</sup> (rs2581830), which  
918 was also the top SNP in eMERGE. The red star represents the imputed FM-eSTR.

919 **(f) Imputed *RFT1* repeat number is positively correlated with height.** The x-axis shows the  
920 mean number of AC repeats. The y-axis shows the mean normalized height for all samples  
921 included in the analysis with a given genotype. Vertical black lines show +/- 1 s.d.

922 **(g) Reporter assay shows expected positive trend between FM-eSTR repeat number and**  
923 **luciferase expression.** Top: schematic of the experimental design (not to scale). A variable  
924 number of AC repeats plus surrounding genomic context (hg19 chr3:53128201-53128577) were  
925 introduced upstream of a minimal promoter driving reporter expression. Bottom: white bar shows  
926 results from the unmodified plasmid (empty). Gray bars show expression results for constructs  
927 with each number of repeats (0, 5, 10, and 12). Reporter expression results normalized to a  
928 Renilla control. Error bars show +/- 1 s.d. Asterisks represent significant differences between  
929 conditions (one-sided t-test p<0.01).

930

931 **Figure 5: Summary of FM-eSTRs classes and potential regulatory mechanisms**

932 **(a) Distribution of FM-eSTR classes across genomic annotations.** Each bar shows the  
933 fraction of FM-eSTRs falling in each annotation consisting of homopolymer (gray), dinucleotide  
934 (red), trinucleotide (orange), tetranucleotide (blue), pentanucleotide (green) or hexanucleotide  
935 (purple) repeats. The total number of FM-eSTRs and the top five most common repeat units in  
936 each category are shown on the right. Note, FM-eSTRs may be counted in more than one  
937 category.

938 **(b) Homopolymer A/T STRs are predicted to modulate nucleosome positioning.**  
939 Homopolymer repeats are depleted of nucleosomes (gray circles) and may modulate expression  
940 changes in nearby genes through altering nucleosome positioning.

941 **(c) GC-rich STRs form DNA and RNA secondary structures during transcription.** Highly  
942 stable secondary structures such as G4 quadruplexes may act by expelling nucleosomes (gray  
943 circle) or stabilizing RNAPII (light green circle). These structures may form in DNA (black) or RNA  
944 (purple). The stability of the structure can depend on the number of repeats.

945 **(d) Dinucleotide STRs can alter transcription factor binding.** Dinucleotides are prevalent in  
946 putative enhancer regions. They may potentially alter transcription factor binding by forming  
947 binding sites themselves (top), changing affinity of nearby binding sites (middle), or modulating  
948 spacing between nearby binding sites (bottom).

949 For **(b)-(d)**, text and arrows in the white boxes provide a summary of the predicted eSTR  
950 mechanism depicted in each panel.

## 951 References

952 1 Visscher, P. M. *et al.* 10 Years of GWAS Discovery: Biology, Function, and Translation.  
953 *Am J Hum Genet* **101**, 5-22, doi:10.1016/j.ajhg.2017.06.005 (2017).

954 2 Edwards, S. L., Beesley, J., French, J. D. & Dunning, A. M. Beyond GWASs: illuminating  
955 the dark road from association to function. *Am J Hum Genet* **93**, 779-797,  
956 doi:10.1016/j.ajhg.2013.10.012 (2013).

957 3 Lappalainen, T. *et al.* Transcriptome and genome sequencing uncovers functional  
958 variation in humans. *Nature* **501**, 506-511, doi:10.1038/nature12531 (2013).

959 4 Gamazon, E. R. *et al.* A gene-based association method for mapping traits using  
960 reference transcriptome data. *Nat Genet* **47**, 1091-1098, doi:10.1038/ng.3367 (2015).

961 5 Gusev, A. *et al.* Integrative approaches for large-scale transcriptome-wide association  
962 studies. *Nat Genet* **48**, 245-252, doi:10.1038/ng.3506 (2016).

963 6 Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts  
964 complex trait gene targets. *Nat Genet* **48**, 481-487, doi:10.1038/ng.3538 (2016).

965 7 Hormozdiari, F., Kostem, E., Kang, E. Y., Pasaniuc, B. & Eskin, E. Identifying causal  
966 variants at loci with multiple signals of association. *Genetics* **198**, 497-508,  
967 doi:10.1534/genetics.114.167908 (2014).

968 8 Kichaev, G. *et al.* Integrating functional data to prioritize causal variants in statistical  
969 fine-mapping studies. *PLoS Genet* **10**, e1004722, doi:10.1371/journal.pgen.1004722  
970 (2014).

971 9 Pickrell, J. K. Joint analysis of functional genomic data and genome-wide association  
972 studies of 18 human traits. *Am. J. Hum. Genet.* **94**, 559-573,  
973 doi:10.1016/j.ajhg.2014.03.004 (2014).

974 10 Grunewald, T. G. P. *et al.* Chimeric EWSR1-FLI1 regulates the Ewing sarcoma  
975 susceptibility gene EGR2 via a GGAA microsatellite. *Nat. Genet.* **47**, 1073-1078,  
976 doi:10.1038/ng.3363 (2015).

977 11 Boettger, L. M. *et al.* Recurring exon deletions in the HP (haptoglobin) gene contribute  
978 to lower blood cholesterol levels. *Nat Genet* **48**, 359-366, doi:10.1038/ng.3510 (2016).

979 12 Leffler, E. M. *et al.* Resistance to malaria through structural variation of red blood cell  
980 invasion receptors. *Science* **356**, doi:10.1126/science.aam6393 (2017).

981 13 Sekar, A. *et al.* Schizophrenia risk from complex variation of complement component 4.  
982 *Nature* **530**, 177-183, doi:10.1038/nature16549 (2016).

983 14 Sun, J. X. *et al.* A direct characterization of human mutation based on microsatellites.  
984 *Nat. Genet.* **44**, 1161-1165, doi:10.1038/ng.2398 (2012).

985 15 Lynch, M. Rate, molecular spectrum, and consequences of human mutation. *Proc Natl  
986 Acad Sci U S A* **107**, 961-968, doi:10.1073/pnas.0912629107 (2010).

987 16 Willems, T. *et al.* Population-Scale Sequencing Data Enable Precise Estimates of Y-STR  
988 Mutation Rates. *Am. J. Hum. Genet.* **98**, 919-933, doi:10.1016/j.ajhg.2016.04.001 (2016).

989 17 Mirkin, S. M. Expandable DNA repeats and human disease. *Nature* **447**, 932-940,  
990 doi:10.1038/nature05977 (2007).

991 18 Willems, T. *et al.* The landscape of human STR variation. *Genome Res.* **24**, 1894-1904,  
992 doi:10.1101/gr.177774.114 (2014).

993 19 Li, H. Towards Better Understanding of Artifacts in Variant Calling from High-Coverage  
994 Samples. *arXiv [q-bio.GN]* (2014).

995 20 Gymrek, M. *et al.* Abundant contribution of short tandem repeats to gene expression  
996 variation in humans. *Nat Genet* **48**, 22-29, doi:10.1038/ng.3461 (2016).

997 21 Nasrallah, M. P. *et al.* Differential effects of a polyalanine tract expansion in Arx on  
998 neural development and gene expression. *Hum Mol Genet* **21**, 1090-1098,  
999 doi:10.1093/hmg/ddr538 (2012).

1000 22 Quilez, J. *et al.* Polymorphic tandem repeats within gene promoters act as modifiers of  
1001 gene expression and DNA methylation in humans. *Nucleic Acids Res.* **44**, 3750-3762,  
1002 doi:10.1093/nar/gkw219 (2016).

1003 23 Vinces, M. D., Legendre, M., Caldara, M., Hagiwara, M. & Verstrepen, K. J. Unstable  
1004 tandem repeats in promoters confer transcriptional evolvability. *Science* **324**, 1213-  
1005 1216, doi:10.1126/science.1170097 (2009).

1006 24 Gemayel, R., Vinces, M. D., Legendre, M. & Verstrepen, K. J. Variable tandem repeats  
1007 accelerate evolution of coding and regulatory sequences. *Annu Rev Genet* **44**, 445-477,  
1008 doi:10.1146/annurev-genet-072610-155046 (2010).

1009 25 Liu, X. S. *et al.* Rescue of Fragile X Syndrome Neurons by DNA Methylation Editing of the  
1010 FMR1 Gene. *Cell* **172**, 979-992 e976, doi:10.1016/j.cell.2018.01.012 (2018).

1011 26 Raveh-Sadka, T. *et al.* Manipulating nucleosome disfavoring sequences allows fine-tune  
1012 regulation of gene expression in yeast. *Nat Genet* **44**, 743-750, doi:10.1038/ng.2305  
1013 (2012).

1014 27 Suter, B., Schnappauf, G. & Thoma, F. Poly(dA.dT) sequences exist as rigid DNA  
1015 structures in nucleosome-free yeast promoters in vivo. *Nucleic Acids Res* **28**, 4083-4089,  
1016 doi:10.1093/nar/28.21.4083 (2000).

1017 28 Afek, A., Schipper, J. L., Horton, J., Gordan, R. & Lukatsky, D. B. Protein-DNA binding in  
1018 the absence of specific base-pair recognition. *Proc Natl Acad Sci U S A* **111**, 17140-  
1019 17145, doi:10.1073/pnas.1410569111 (2014).

1020 29 Conlon, E. G. *et al.* The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions  
1021 and sequesters hnRNP H to disrupt splicing in ALS brains. *eLife* **5**,  
1022 doi:10.7554/eLife.17820 (2016).

1023 30 Lin, Y., Dent, S. Y., Wilson, J. H., Wells, R. D. & Napierala, M. R loops stimulate genetic  
1024 instability of CTG.CAG repeats. *Proc Natl Acad Sci U S A* **107**, 692-697,  
1025 doi:10.1073/pnas.0909740107 (2010).

1026 31 Rothenburg, S., Koch-Nolte, F., Rich, A. & Haag, F. A polymorphic dinucleotide repeat in  
1027 the rat nucleolin gene forms Z-DNA and inhibits promoter activity. *Proc. Natl. Acad. Sci.  
U. S. A.* **98**, 8985-8990, doi:10.1073/pnas.121176998 (2001).

1029 32 Min, J. L. *et al.* The use of genome-wide eQTL associations in lymphoblastoid cell lines to  
1030 identify novel genetic pathways involved in complex traits. *PLoS One* **6**, e22070,  
1031 doi:10.1371/journal.pone.0022070 (2011).

1032 33 Consortium, G. *et al.* Genetic effects on gene expression across human tissues. *Nature*  
1033 **550**, 204-213, doi:10.1038/nature24277 (2017).

1034 34 Willems, T. *et al.* Genome-wide profiling of heritable and de novo STR variations. *Nat.  
Methods*, doi:10.1038/nmeth.4267 (2017).

1036 35 Borel, C. *et al.* Tandem repeat sequence variation as causative cis-eQTLs for protein-  
1037 coding gene expression variation: the case of CSTB. *Hum. Mutat.* **33**, 1302-1309,  
1038 doi:10.1002/humu.22115 (2012).

1039 36 Contente, A., Dittmer, A., Koch, M. C., Roth, J. & Dobbelstein, M. A polymorphic  
1040 microsatellite that mediates induction of PIG3 by p53. *Nat. Genet.* **30**, 315-320,  
1041 doi:10.1038/ng836 (2002).

1042 37 Gebhardt, F., Zänker, K. S. & Brandt, B. Modulation of epidermal growth factor receptor  
1043 gene transcription by a polymorphic dinucleotide repeat in intron 1. *J. Biol. Chem.* **274**,  
1044 13176-13180 (1999).

1045 38 Johnson, A. D. *et al.* Genome-wide association meta-analysis for total serum bilirubin  
1046 levels. *Hum Mol Genet* **18**, 2700-2710, doi:10.1093/hmg/ddp202 (2009).

1047 39 Matsuzono, K. *et al.* Antisense Oligonucleotides Reduce RNA Foci in Spinocerebellar  
1048 Ataxia 36 Patient iPSCs. *Mol Ther Nucleic Acids* **8**, 211-219,  
1049 doi:10.1016/j.omtn.2017.06.017 (2017).

1050 40 Saha, A. *et al.* Functional IFNG polymorphism in intron 1 in association with an increased  
1051 risk to promote sporadic breast cancer. *Immunogenetics* **57**, 165-171,  
1052 doi:10.1007/s00251-005-0783-5 (2005).

1053 41 Shimajiri, S. *et al.* Shortened microsatellite d(CA)21 sequence down-regulates promoter  
1054 activity of matrix metalloproteinase 9 gene. *FEBS Lett.* **455**, 70-74 (1999).

1055 42 Vikman, S. *et al.* Functional analysis of 5-lipoxygenase promoter repeat variants. *Hum*  
1056 *Mol Genet* **18**, 4521-4529, doi:10.1093/hmg/ddp414 (2009).

1057 43 Urbut, S. M., Wang, G., Carbonetto, P. & Stephens, M. Flexible statistical methods for  
1058 estimating and testing effects in genomic studies with multiple conditions. *Nat Genet*  
1059 **51**, 187-195, doi:10.1038/s41588-018-0268-8 (2019).

1060 44 Jiang, C. & Pugh, B. F. Nucleosome positioning and gene regulation: advances through  
1061 genomics. *Nat Rev Genet* **10**, 161-172, doi:10.1038/nrg2522 (2009).

1062 45 Bochman, M. L., Paeschke, K. & Zakian, V. A. DNA secondary structures: stability and  
1063 function of G-quadruplex structures. *Nat Rev Genet* **13**, 770-780, doi:10.1038/nrg3296  
1064 (2012).

1065 46 Sawaya, S. *et al.* Microsatellite tandem repeats are abundant in human promoters and  
1066 are associated with regulatory elements. *PLoS One* **8**, e54710,  
1067 doi:10.1371/journal.pone.0054710 (2013).

1068 47 Todd, A. K., Johnston, M. & Neidle, S. Highly prevalent putative quadruplex sequence  
1069 motifs in human DNA. *Nucleic Acids Res* **33**, 2901-2907, doi:10.1093/nar/gki553 (2005).

1070 48 Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic*  
1071 *Acids Res* **31**, 3406-3415, doi:10.1093/nar/gkg595 (2003).

1072 49 Hansel-Hertsch, R. *et al.* G-quadruplex structures mark human regulatory chromatin.  
1073 *Nat Genet* **48**, 1267-1272, doi:10.1038/ng.3662 (2016).

1074 50 MacArthur, J. *et al.* The new NHGRI-EBI Catalog of published genome-wide association  
1075 studies (GWAS Catalog). *Nucleic Acids Res* **45**, D896-D901, doi:10.1093/nar/gkw1133  
1076 (2017).

1077 51 Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height and body  
1078 mass index in ~700,000 individuals of European ancestry. *bioRxiv*, doi:10.1101/274654  
1079 (2018).

1080 52 Schizophrenia Working Group of the Psychiatric Genomics, C. Biological insights from  
1081 108 schizophrenia-associated genetic loci. *Nature* **511**, 421-427,  
1082 doi:10.1038/nature13595 (2014).

1083 53 Huang, H. *et al.* Fine-mapping inflammatory bowel disease loci to single-variant  
1084 resolution. *Nature* **547**, 173-178, doi:10.1038/nature22969 (2017).

1085 54 Savage, J. E. *et al.* Genome-wide association meta-analysis in 269,867 individuals  
1086 identifies new genetic and functional links to intelligence. *Nat Genet* **50**, 912-919,  
1087 doi:10.1038/s41588-018-0152-6 (2018).

1088 55 Guo, H. *et al.* Integration of disease association and eQTL data using a Bayesian  
1089 colocalisation approach highlights six candidate causal genes in immune-mediated  
1090 diseases. *Hum Mol Genet* **24**, 3305-3313, doi:10.1093/hmg/ddv077 (2015).

1091 56 Haeuptle, M. A. *et al.* Human RFT1 deficiency leads to a disorder of N-linked  
1092 glycosylation. *Am J Hum Genet* **82**, 600-606, doi:10.1016/j.ajhg.2007.12.021 (2008).

1093 57 Saini, S., Mitra, I., Mousavi, N., Fotsing, S. F. & Gymrek, M. A reference haplotype panel  
1094 for genome-wide imputation of short tandem repeats. *Nat. Commun.* **9**, 4397,  
1095 doi:10.1038/s41467-018-06694-0 (2018).

1096 58 Chiang, C. *et al.* The impact of structural variation on human gene expression. *Nat Genet*  
1097 **49**, 692-699, doi:10.1038/ng.3834 (2017).

1098 59 Hasler, J. & Strub, K. Alu elements as regulators of gene expression. *Nucleic Acids Res* **34**,  
1099 5491-5497, doi:10.1093/nar/gkl706 (2006).

1100 60 Kent, W. J. *et al.* The human genome browser at UCSC. *Genome Res.* **12**, 996-1006,  
1101 doi:10.1101/gr.229102. Article published online before print in May 2002 (2002).

1102 61 Genomes Project, C. *et al.* A global reference for human genetic variation. *Nature* **526**,  
1103 68-74, doi:10.1038/nature15393 (2015).

1104 62 Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based  
1105 linkage analyses. *Am J Hum Genet* **81**, 559-575, doi:10.1086/519795 (2007).

1106 63 Patterson, N., Price, A. L. & Reich, D. Population structure and eigenanalysis. *PLoS Genet*  
1107 **2**, e190, doi:10.1371/journal.pgen.0020190 (2006).

1108 64 Price, A. L. *et al.* Principal components analysis corrects for stratification in genome-  
1109 wide association studies. *Nat Genet* **38**, 904-909, doi:10.1038/ng1847 (2006).

1110 65 Stegle, O., Parts, L., Piipari, M., Winn, J. & Durbin, R. Using probabilistic estimation of  
1111 expression residuals (PEER) to obtain increased power and interpretability of gene  
1112 expression analyses. *Nat Protoc* **7**, 500-507, doi:10.1038/nprot.2011.457 (2012).

1113 66 Seabold, S. P., Josef. Statsmodels: Econometric and statistical modeling with python.  
1114 *Proceedings of the 9th Python in Science Conference* (2010).


1115 67 Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic  
1116 features. *Bioinformatics* **26**, 841-842, doi:10.1093/bioinformatics/btq033 (2010).

1117 68 Heinz, S. *et al.* Simple combinations of lineage-determining transcription factors prime  
1118 cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* **38**, 576-  
1119 589, doi:10.1016/j.molcel.2010.05.004 (2010).


1120 69 Wang, Y. *et al.* The 3D Genome Browser: a web-based browser for visualizing 3D  
1121 genome organization and long-range chromatin interactions. *Genome Biol* **19**, 151,  
1122 doi:10.1186/s13059-018-1519-9 (2018).

1123 70 Mifsud, B. *et al.* Mapping long-range promoter contacts in human cells with high-  
1124 resolution capture Hi-C. *Nat Genet* **47**, 598-606, doi:10.1038/ng.3286 (2015).  
1125 71 Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation  
1126 method for the next generation of genome-wide association studies. *PLoS Genet.* **5**,  
1127 e1000529, doi:10.1371/journal.pgen.1000529 (2009).  
1128 72 Browning, B. L., Zhou, Y. & Browning, S. R. A One-Penny Imputed Genome from Next-  
1129 Generation Reference Panels. *Am J Hum Genet* **103**, 338-348,  
1130 doi:10.1016/j.ajhg.2018.07.015 (2018).  
1131 73 Lalioti, M. D. *et al.* Dodecamer repeat expansion in cystatin B gene in progressive  
1132 myoclonus epilepsy. *Nature* **386**, 847-851, doi:10.1038/386847a0 (1997).  
1133 74 Kobayashi, H. *et al.* Expansion of intronic GGCCTG hexanucleotide repeat in NOP56  
1134 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron  
1135 involvement. *Am J Hum Genet* **89**, 121-130, doi:10.1016/j.ajhg.2011.05.015 (2011).  
1136 75 Mougey, E. *et al.* ALOX5 polymorphism associates with increased leukotriene production  
1137 and reduced lung function and asthma control in children with poorly controlled  
1138 asthma. *Clin Exp Allergy* **43**, 512-520, doi:10.1111/cea.12076 (2013).  
1139 76 Stephensen, C. B. *et al.* ALOX5 gene variants affect eicosanoid production and response  
1140 to fish oil supplementation. *J Lipid Res* **52**, 991-1003, doi:10.1194/jlr.P012864 (2011).  
1141


a




b




d




c






**a**



**b**

**g**



**c**

DNA (+ strand)

**d**

RNA (+ strand)

DNA (+ strand)

RNA (+ strand)

**e**

**f**

**h**

**i**

**j**

**g**

**h**


**i**

**j**


**h**

**i**


**a**




**b**




**c**




**d**




**e**




**g**




**f**




**a**




**b**




**c**



**d**




**Supplementary Figure 1: Analysis of GTEx population structure**




Principal component analysis was performed using SNP genotypes from the GTEx and 1000 Genomes cohorts. Samples from the 1000 Genomes project are shown in gray and GTEx samples are shown as colored dots based on ethnicity provided for each sample (yellow=African American; red=Amerindian; blue=Asian; green=European, black=Unknown). Related to Fig. 1.

**Supplementary Figure 2: Effect of varying numbers of PEER factors on power to detect eSTRs**




eSTRs (gene-level FDR 10%) were computed for each tissue after adjusting for a number of PEER factors ranging from 0 to 50. The x-axis shows the number of PEER factors adjusted for. The y-axis shows the number of significant eSTRs. Dashed vertical lines show the number of PEER factors equal to  $N/10$ , where  $N$  is the number of samples analyzed for each tissue. Purple=whole blood, yellow=Brain-Cerebellum, gold=Nerve-Tibial. Related to Fig. 1.

**Supplementary Figure 3: Correlation of sample metadata with PEER factors**




Each cell in the matrix shows the Spearman correlation of each PEER factor with data processing covariates. The x-axis represents each variable as defined for the GTEx cohort in dbGaP study phs000424.v7.p2. For example, covariates most strongly associated with PEER factors included DTHHRDY (Hardy scale for death classification) and TRISCHD (ischemic time). The y-axis represents factors obtained from PEER analysis of gene expression from Adipose-subcutaneous tissue. Similar correlations were observed for other tissues. Related to Fig. 1.

**Supplementary Figure 4: Relationship between sample size and number of eSTRs detected**




The x-axis shows the number of samples per tissue. The y-axis shows the number of eSTRs (gene-level FDR<10%) detected in each tissue. Each dot represents a single tissue, using the same colors as shown in **Fig. 1** in the main text (box on the right). Related to Fig. 1.

**Supplementary Figure 5: Enrichment of genomic annotations as a function of CAVIAR threshold**




The x-axis represents CAVIAR threshold in terms of the percentile across all eSTRs. The y-axis represents the odds ratio for enrichment in eSTRs above each percentile threshold in each of these categories: **a.** 5'UTRs (purple); **b.** 3'UTRs (blue); **c.** promoters (orange; within 3kb of a transcription start site); **d.** Coding regions (red) and **e.** Intergenic regions (green). Related to Fig. 1.

**Supplementary Figure 6: Difference in CAVIAR score between the top eSTR and top eSNP for each gene**




For each tissue, the boxplot shows the distribution of differences between the CAVIAR posterior score for the best STR vs. the best SNP for each gene. Data is only shown for genes with FM-eSTRs. The colors of each box correspond to the different tissues (see legend on the right and the same as in **Fig. 1b**). Boxplots as in **Fig. 1c**. Outlier points are not shown. Related to Fig. 1.

## Supplementary Figure 7: Example multi-allelic FM-eSTRs




For each plot, the x-axis represents the mean number of repeats in each individual and the y-axis represents normalized expression in the tissue for which the eSTR was most significant. Boxplots summarize the distribution of expression values for each genotype. Boxplots as in **Fig. 1c**. The red line shows the mean expression for each x-axis value. Related to Fig. 1.

**Supplementary Figure 8: Pairwise sharing of effect sizes across tissues**




For each discovery tissue (rows), all eSTRs with gene-level FDR<10% were tested for association in each other (replication) tissue (columns). The value in each cell gives the percent of eSTRs that were replicated with  $p<0.05$  ( $\pi_1$ ). Related to Fig. 1.

**Supplementary Figure 9: Sharing of eSTRs across tissues**




The x-axis represents the number of tissues that share a given eSTR (absolute value of mashR Z-score >4). The y-axis represents the number of eSTRs shared across a given number of tissues. Related to Fig. 1.

### Supplementary Figure 10: Localization of all STRs around putative regulatory regions




Left and right plots show localization around transcription start sites and DNAse1 HS clusters, respectively. The y-axis denotes the relative number of STRs of each type in each bin. For promoters, the x-axis is divided into 100bp bins. For DNAse1 HS sites, the x-axis is divided into 50bp bins. In each plot, values were smoothed by taking a sliding average of each four consecutive bins. Only STR-gene pairs included in our analysis are considered. Each plot compares localization of the two possible sequences of a given repeat unit on the coding strand. *i.e.* top plots compare repeat units of the form  $C_nG$  vs. their reverse complement on the opposite strand, middle plots compare AC vs. GT repeats, and bottom plots compare A vs. T repeats. The strand of each STR was determined based on the coding strand of each target gene. Related to Fig. 2.

**Supplementary Figure 11: Nucleosome occupancy and DNasel hypersensitivity show distinct patterns around eSTRs**




**a-c. Nucleosome density around STRs with different repeat unit lengths.** Nucleosome density in GM12878 in 5bp windows is averaged across all STRs analyzed (dashed) and FM-eSTRs (solid) relative to the center of the STR. **b. DNasel HS density around STRs with different repeat unit lengths.** The number of DNasel HS reads in GM12878 (gray), fat (red), tibial nerve (yellow), and skin (cyan) is averaged across all STRs in each category. Solid lines show FM-eSTRs. Dashed lines show all STRs. Left=homopolymers, middle=dinucleotides, right=tetranucleotides. Other repeat unit lengths were excluded since they have low numbers of FM-eSTRs (see Fig. 5a). Dashed vertical lines in (d) show the STR position +/- 147bp. Related to Fig. 2.

### Supplementary Figure 12: Bias in the direction of eSTR effect sizes




The y-axis shows the percentage of FM-eSTRs in each category with positive effect sizes, meaning a positive correlation between STR length and expression. Colored bars represent different repeat unit lengths (black=all FM-eSTRs; gray=homopolymers; red=dinucleotides; gold=trinucleotides; blue=tetranucleotides; purple=pentanucleotides; green=hexanucleotides). Error bars show 95% confidence intervals. Asterisks denote categories that are nominally significant (binomial two-sided  $p < 0.05$ ) for having significantly more or less positive effect sizes than expected by chance (50%). No category was significant after accounting for multiple hypothesis testing. Related to Fig. 2.

**Supplementary Figure 13: Characterization of tissue-specific FM-eSTRs**




FM-eSTRs were clustered by absolute Z-scores computed by mashR using K-means (**Methods**). The heatmap shows absolute values of Z-scores in each tissue, Z-normalized by row. (Number of genes in each cluster: Cluster 1=22, Cluster 2=497, Cluster 3=253; Cluster 4=122, Cluster 5=90, Cluster 6=126, Cluster 7=220, Cluster 8=336). Related to Fig. 2.

**Supplementary Figure 14: Characterization of tissue-specific eSTRs**




Each panel shows the distribution of the absolute value of posterior effect sizes computed by mashR in each tissue for the set of FM-eSTRs in each cluster (see **Supp Fig. 13** above). Horizontal lines show median values, boxes span from the 25th percentile (Q1) to the 75th percentile (Q3). Whiskers extend to  $Q1-1.5*IQR$  (bottom) and  $Q3+1.5*IQR$  (top), where IQR gives the interquartile range ( $Q3-Q1$ ). The red line shows the mean expression for each x-axis value. Related to Fig. 2.

### Supplementary Figure 15: eSTR repeat unit enrichment




We evaluated repeat unit enrichment in multiple FM-eSTR groups: all FM-eSTRs combined across tissues (similar to **Fig. 2e**), FM-eSTRs identified per-tissue, and FM-eSTRs belonging to each cluster (see **Supplementary Fig. 13**). For each group of FM-eSTRs, the heatmap shows the  $\log_2$  of the odds ratio computed using a Fisher's Exact test (scipy.stats.fisher\_exact). Columns are sorted from highest to lowest enrichment in all FM-eSTRs. Bold boxes indicate enrichments statistically significant (adjusted  $p < 0.05$ , adjusted separately per row for the number of motifs tested). Related to Fig. 2.

### Supplementary Figure 16: Density of RNAPII localization around STRs




The y-axis shows the average number of ChIP-seq reads for RNA Polymerase II in 5bp bins centered at STRs within 5KB of TSSs. Black lines denote all STRs, blue lines denote CCG STRs, and red lines denote STRs matching the canonical G4 motif. Dashed lines represent all STRs of each class and solid lines represent FM-eSTRs. Plots show read counts in different cell types. From top to bottom: human embryonic stem cells, heart, lung, and tibial nerve. Related to Fig. 3.

**Supplementary Figure 17: GC-rich eSTRs modulate DNA or RNA secondary structure**




**(a-b) Free energy of STR regions.** Boxplots denote the distribution of free energy for each STR +/- 50bp of context sequence, computed as the average across all alleles at each STR. **(a)** and **(b)** show results computed using the non-template strand for DNA and RNA respectively. **(c-d) Pearson correlation between STR length and free energy.** Correlations were computed separately for each STR, and plots show the distribution of correlation coefficients across all STRs. The dashed horizontal line denotes 0 correlation as expected by chance. **(c)** and **(d)** show results computed using the non-template strand for DNA and RNA respectively. Nominally significant (Mann Whitney one-sided  $p<0.05$ ) differences between distributions are denoted with a single asterisk. Differences significant after controlling for multiple hypothesis correction are denoted with double asterisks. For each category (free energy and Pearson correlation), we used a Bonferroni correction to control for 20 total comparisons: comparing all vs. FM-eSTRs separately in each category, comparing CCG vs. all STRs, and comparing G4 vs. all STRs, in four conditions (DNA +/- and RNA +/-). Related to Fig. 3.

## Supplementary Figure 18: Example GWAS signals co-localized with FM-eSTRs



Left: For each plot, the x-axis represents the mean number of repeats in each individual and the y-axis represents normalized expression in the tissue with the most significant eSTR signal at each locus. Boxplots summarize the distribution of expression values for each genotype. Box plots as in **Fig. 1c**. The red line shows the mean expression for each x-axis value. Right: Top panels give genes in each region. The target gene for the eQTL associations is shown in black. Middle panels give the  $-\log_{10}$  p-values of association of the effect-size between each SNP (black points) and the expression of the target gene. The FM-eSTR is denoted by a red star. Bottom panels give the  $-\log_{10}$  p-values of association between each SNP and the trait based on published GWAS summary statistics. Dashed gray horizontal lines give the genome-wide significance threshold of 5E-8. Related to Fig. 4.

**Supplementary Figure 19: Example GWAS signal for schizophrenia potentially driven by an eSTR for *MED19***



**a. eSTR association for *MED19*.** The x-axis shows STR genotypes at an AC repeat (chr11:57523883) as the mean number of repeats in each individual and the y-axis shows normalized *MED19* expression in subcutaneous adipose. Each point represents a single individual. Red lines show the mean expression for each x-axis value. Boxplots as in Fig. 1c. **b. Summary statistics for *MED19* expression and schizophrenia.** The top panel shows genes in the region around *MED19*. The middle panel shows the  $-\log_{10}$  p-values of association between each variant and *MED19* expression in subcutaneous adipose tissue in the GTEx cohort. The FM-eSTR is denoted by a red star. The bottom panel shows the  $-\log_{10}$  p-values of association for each variant with schizophrenia from Ripke, et al.. The dashed gray horizontal line shows genome-wide significance threshold of 5E-8. **c. Detailed view of the *MED19* locus.** A UCSC genome browser screenshot is shown for the region in the gray box in (b). The FM-eSTR is shown in red [(AC)<sub>n</sub>]. The bottom track shows transcription factor (TF) and chromatin regulator binding sites profiled by ENCODE. The bottom panel shows long-range interactions reported by Mifsud, et al. using Capture Hi-C on GM12878. Interactions shown in black include *MED19*. Interactions to loci outside of the window depicted are not shown. Related to Fig. 4.

See file eSTRGtex\_SuppTables.xlsx for Supplementary Tables 1-8.